NeueHealth (NEUE) 10-Q 12 Aug 22 2022 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2022	Aug. 05, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-40537
Entity Registrant Name	BRIGHT HEALTH GROUP, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-4991296
Entity Address, Address Line One	8000 Norman Center Drive, Suite 1200
Entity Address, City or Town	Minneapolis
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55437
City Area Code	612
Local Phone Number	238-1321
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	BHG
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		629,698,944
Entity Central Index Key	0001671284
Amendment Flag	false
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 1,427,517,000	$ 1,061,179,000
Short-term investments	833,923,000	193,835,000
Accounts receivable, net of allowance of $6,737 and $4,074, respectively	144,878,000	113,474,000
Direct contracting performance year receivable	396,104,000	0
Prepaids and other current assets	357,989,000	291,712,000
Total current assets	3,160,411,000	1,660,200,000
Other assets:
Long-term investments	861,675,000	675,192,000
Property, equipment and capitalized software, net	47,937,000	38,344,000
Goodwill	835,450,000	835,140,000
Intangible assets, net	316,249,000	343,860,000
Other non-current assets	39,335,000	45,603,000
Total other assets	2,100,646,000	1,938,139,000
Total assets	5,261,057,000	3,598,339,000
Current liabilities:
Medical costs payable	1,049,874,000	817,975,000
Accounts payable	120,541,000	118,140,000
Unearned revenue	56,872,000	53,295,000
Risk adjustment payable	1,847,883,000	931,170,000
Direct contracting performance year obligation	310,603,000	0
Short-term borrowings	0	155,000,000
Other current liabilities	245,276,000	207,238,000
Total current liabilities	3,631,049,000	2,282,818,000
Other liabilities	36,091,000	41,994,000
Total liabilities	3,667,140,000	2,324,812,000
Commitments and contingencies (Note 10)
Redeemable noncontrolling interests	164,454,000	128,407,000
Series A redeemable preferred stock, $0.0001 par value; 100,000,000 shares authorized in 2022 and 2021; 750,000 and — shares issued and outstanding in 2022 and 2021, respectively	747,481,000	0
Shareholders’ equity (deficit):
Common stock, $0.0001 par value; 3,000,000,000 shares authorized in 2022 and 2021; 629,322,217 and 628,622,872 shares issued and outstanding in 2022 and 2021, respectively	63,000	63,000
Additional paid-in capital	2,915,056,000	2,861,243,000
Accumulated deficit	(2,170,751,000)	(1,700,851,000)
Accumulated other comprehensive loss	(50,386,000)	(3,335,000)
Treasury stock, at cost, 2,522,148 shares at June 30, 2022 and December 31, 2021, respectively	(12,000,000)	(12,000,000)
Total shareholders’ equity (deficit)	681,982,000	1,145,120,000
Total liabilities, redeemable noncontrolling interests, redeemable preferred stock and shareholders’ equity (deficit)	$ 5,261,057,000	$ 3,598,339,000

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Accounts receivable, allowance for credit loss	$ 6,737	$ 4,074
Series A redeemable preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Series A redeemable preferred stock, shares authorized (in shares)	100,000,000	100,000,000
Series A redeemable preferred stock, shares issued (in shares)	750,000	0
Series A redeemable preferred stock, shares outstanding (in shares)	750,000	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	3,000,000,000	3,000,000,000
Common stock, shares issued (in shares)	629,322,217	628,622,872
Common stock, shares outstanding (in shares)	629,322,217	628,622,872
Treasury stock, at cost (in shares)	2,522,148	2,522,148

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue:
Premium revenue	$ 1,437,329	$ 1,042,086	$ 3,117,779	$ 1,902,717
Direct contracting revenue	137,205	0	320,002	0
Service revenue	$ 12,845	$ 12,085	$ 25,273	$ 20,523
Revenue, Product and Service [Extensible Enumeration]	Service [Member]	Service [Member]	Service [Member]	Service [Member]
Investment income (loss)	$ (10,751)	$ 59,669	$ (50,851)	$ 65,158
Total revenue	1,576,628	1,113,840	3,412,203	1,988,398
Operating expenses:
Medical costs	1,398,166	904,630	2,978,762	1,589,200
Operating costs	413,320	261,060	832,238	469,300
Depreciation and amortization	13,229	7,195	26,270	11,776
Total operating expenses	1,824,715	1,172,885	3,837,270	2,070,276
Operating loss	(248,087)	(59,045)	(425,067)	(81,878)
Interest expense	337	4,142	1,530	4,688
Other income	2	0	(782)	0
Loss before income taxes	(248,426)	(63,187)	(425,815)	(86,566)
Income tax (benefit) expense	2,904	(19,464)	6,144	(18,298)
Net loss	(251,330)	(43,723)	(431,959)	(68,268)
Net earnings attributable to noncontrolling interests	(23,336)	(795)	(37,941)	(1,412)
Series A preferred stock dividend accrued	(9,461)	0	(18,399)	0
Net loss attributable to Bright Health Group, Inc. common shareholders	$ (284,127)	$ (44,518)	$ (488,299)	$ (69,680)
Basic loss per share attributable to Bright Health Groups, Inc. common shareholders (in dollars per share)	$ (0.45)	$ (0.28)	$ (0.78)	$ (0.46)
Diluted loss per share attributable to Bright Health Groups, Inc. common shareholders (in dollars per share)	$ (0.45)	$ (0.28)	$ (0.78)	$ (0.46)
Basic weighted-average common shares outstanding (in shares)	629,201	160,942	628,984	150,616
Diluted weighted-average common shares outstanding (in shares)	629,201	160,942	628,984	150,616

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (251,330)	$ (43,723)	$ (431,959)	$ (68,268)
Other comprehensive (loss) income:
Unrealized investment holding losses arising during the year, net of tax of $0 and $0, respectively	(21,469)	(684)	(49,558)	(1,665)
Less: reclassification adjustments for investment (losses) gains, net of tax of $0 and $0, respectively	(758)	167	(2,507)	228
Other comprehensive (loss) income	(20,711)	(851)	(47,051)	(1,893)
Comprehensive loss	(272,041)	(44,574)	(479,010)	(70,161)
Comprehensive loss attributable to noncontrolling interests	(23,336)	(795)	(37,941)	(1,412)
Comprehensive loss attributable to Bright Health Group, Inc. common shareholders	$ (295,377)	$ (45,369)	$ (516,951)	$ (71,573)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (PARENTHETICAL) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement of Comprehensive Income [Abstract]
Unrealized investment holding (losses) gains arising during the year, tax	$ 0	$ 0	$ 0	$ 0
Reclassification adjustments for investment gains, tax	$ 0	$ 0	$ 0	$ 0

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE PREFERRED STOCK AND SHAREHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	IPO	Common Stock	Common Stock IPO	Additional Paid-In Capital	Additional Paid-In Capital IPO	Retained Earnings (Deficit)	Accumulated Other Comprehensive Income (Loss)	Treasury Stock
Beginning balance (in shares) at Dec. 31, 2020	164,245,000
Beginning balance at Dec. 31, 2020	$ 1,681,015
Redeemable Preferred Stock
Issuance of preferred stock (in shares)	1,420,000
Issuance of preferred stock	$ 55,137
Ending balance (in shares) at Mar. 31, 2021	165,665,000
Ending balance at Mar. 31, 2021	$ 1,736,152
Beginning balance (in shares) at Dec. 31, 2020			137,663,000
Beginning balance at Dec. 31, 2020	(503,672)		$ 14		$ 9,877		$ (515,989)	$ 2,426	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(25,162)						(25,162)
Issuance of common stock (in shares)			4,661,000
Issuance of common stock	4,893				4,893
Share-based compensation	5,176				5,176
Other comprehensive loss	(1,042)							(1,042)
Ending balance (in shares) at Mar. 31, 2021			142,324,000
Ending balance at Mar. 31, 2021	$ (519,807)		$ 14		19,946		(541,151)	1,384	0
Beginning balance (in shares) at Dec. 31, 2020	164,245,000
Beginning balance at Dec. 31, 2020	$ 1,681,015
Ending balance (in shares) at Jun. 30, 2021	0
Ending balance at Jun. 30, 2021	$ 0
Beginning balance (in shares) at Dec. 31, 2020			137,663,000
Beginning balance at Dec. 31, 2020	(503,672)		$ 14		9,877		(515,989)	2,426	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(69,680)
Other comprehensive loss	(1,893)
Ending balance (in shares) at Jun. 30, 2021			625,691,000
Ending balance at Jun. 30, 2021	$ 2,150,026		$ 63		2,735,099		(585,669)	533	0
Beginning balance (in shares) at Mar. 31, 2021	165,665,000
Beginning balance at Mar. 31, 2021	$ 1,736,152
Redeemable Preferred Stock
Issuance of preferred stock (in shares)	2,067,000
Issuance of preferred stock	$ 79,807
Conversion of preferred stock to common stock, redeemable preferred stock (in shares)	(167,732,000)
Conversion of preferred Stock to common Stock, redeemable preferred stock	$ (1,815,959)
Ending balance (in shares) at Jun. 30, 2021	0
Ending balance at Jun. 30, 2021	$ 0
Beginning balance (in shares) at Mar. 31, 2021			142,324,000
Beginning balance at Mar. 31, 2021	(519,807)		$ 14		19,946		(541,151)	1,384	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(44,518)						(44,518)
Conversion of preferred stock to common stock (in shares)			427,897,000
Conversion of preferred stock to common stock	1,815,959		$ 43		1,815,916
Issuance of common stock (in shares)			4,120,000	51,350,000
Issuance of common stock	4,723	$ 880,642	$ 1	$ 5	4,722	$ 880,637
Share-based compensation	13,878				13,878
Other comprehensive loss	(851)							(851)
Ending balance (in shares) at Jun. 30, 2021			625,691,000
Ending balance at Jun. 30, 2021	$ 2,150,026		$ 63		2,735,099		(585,669)	533	0
Beginning balance (in shares) at Dec. 31, 2021	0
Beginning balance at Dec. 31, 2021	$ 0
Redeemable Preferred Stock
Issuance of preferred stock (in shares)	750,000
Issuance of preferred stock	$ 747,481
Ending balance (in shares) at Mar. 31, 2022	750,000
Ending balance at Mar. 31, 2022	$ 747,481
Beginning balance (in shares) at Dec. 31, 2021	628,622,872		628,623,000
Beginning balance at Dec. 31, 2021	$ 1,145,120		$ 63		2,861,243		(1,700,851)	(3,335)	(12,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(195,234)						(195,234)
Issuance of common stock (in shares)			370,000
Issuance of common stock	257				257
Share-based compensation	32,921				32,921
Other comprehensive loss	(26,340)							(26,340)
Ending balance (in shares) at Mar. 31, 2022			628,993,000
Ending balance at Mar. 31, 2022	$ 956,724		$ 63		2,894,421		(1,896,085)	(29,675)	(12,000)
Beginning balance (in shares) at Dec. 31, 2021	0
Beginning balance at Dec. 31, 2021	$ 0
Ending balance (in shares) at Jun. 30, 2022	750,000
Ending balance at Jun. 30, 2022	$ 747,481
Beginning balance (in shares) at Dec. 31, 2021	628,622,872		628,623,000
Beginning balance at Dec. 31, 2021	$ 1,145,120		$ 63		2,861,243		(1,700,851)	(3,335)	(12,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive loss	$ (47,051)
Ending balance (in shares) at Jun. 30, 2022	629,322,217		629,322,000
Ending balance at Jun. 30, 2022	$ 681,982		$ 63		2,915,056		(2,170,751)	(50,386)	(12,000)
Beginning balance (in shares) at Mar. 31, 2022	750,000
Beginning balance at Mar. 31, 2022	$ 747,481
Ending balance (in shares) at Jun. 30, 2022	750,000
Ending balance at Jun. 30, 2022	$ 747,481
Beginning balance (in shares) at Mar. 31, 2022			628,993,000
Beginning balance at Mar. 31, 2022	956,724		$ 63		2,894,421		(1,896,085)	(29,675)	(12,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(274,666)						(274,666)
Issuance of common stock (in shares)			329,000
Issuance of common stock	415				415
Share-based compensation	20,220				20,220
Other comprehensive loss	$ (20,711)							(20,711)
Ending balance (in shares) at Jun. 30, 2022	629,322,217		629,322,000
Ending balance at Jun. 30, 2022	$ 681,982		$ 63		$ 2,915,056		$ (2,170,751)	$ (50,386)	$ (12,000)

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (431,959,000)	$ (68,268,000)
Net loss attributable to Bright Health Group, Inc. common shareholders		(69,680,000)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	26,270,000	11,776,000
Impairment of intangible assets	6,720,000	0
Share-based compensation	53,141,000	19,054,000
Deferred income taxes	1,154,000	(18,018,000)
Unrealized loss (gain) on equity securities	57,151,000	(62,754,000)
Other, net	4,582,000	8,681,000
Changes in assets and liabilities, net of acquired assets and liabilities:
Accounts receivable	(31,404,000)	(14,427,000)
Direct contracting performance year receivable	(396,104,000)	0
Other assets	(60,991,000)	(39,883,000)
Medical cost payable	231,899,000	223,125,000
Risk adjustment payable	916,713,000	318,758,000
Accounts payable and other liabilities	35,312,000	120,847,000
Unearned revenue	3,577,000	(333,000)
Direct contracting performance year obligation	310,603,000	0
Net cash provided by operating activities	726,664,000	497,146,000
Cash flows from investing activities:
Purchases of investments	(1,140,896,000)	(596,811,000)
Proceeds from sales, paydown, and maturities of investments	204,775,000	449,636,000
Purchases of property and equipment	(15,154,000)	(10,554,000)
Business acquisitions, net of cash acquired	(310,000)	(210,492,000)
Net cash used in investing activities	(951,585,000)	(368,221,000)
Cash flows from financing activities:
Proceeds from issuance of preferred stock	747,481,000	0
Proceeds from issuance of common stock	672,000	9,616,000
Proceeds from short-term borrowings	0	200,000,000
Repayments of short-term borrowings	(155,000,000)	(200,000,000)
Distribution to noncontrolling interest holders	(1,894,000)	0
Payments for debt issuance costs	0	(3,391,000)
Proceeds from IPO	0	887,328,000
Payments for IPO offering costs	0	(4,530,000)
Net cash provided by financing activities	591,259,000	889,023,000
Net increase in cash and cash equivalents	366,338,000	1,017,948,000
Cash and cash equivalents – beginning of year	1,061,179,000	488,371,000
Cash and cash equivalents – end of period	1,427,517,000	1,506,319,000
Supplemental disclosures of cash flow information:
Changes in unrealized (loss) gain on available-for-sale securities in OCI	(47,051,000)	(1,893,000)
Cash paid for interest	1,168,000	3,195,000
Supplemental schedule of non-cash activities:
Redeemable convertible preferred stock issued for acquisitions	0	134,944,000
Conversion of redeemable convertible preferred stock to common stock upon initial public offering	0	1,815,916,000
Offering costs included in accounts payable and accrued expenses	$ 0	$ 2,156,000

ORGANIZATION AND BASIS OF PRESE

ORGANIZATION AND BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BASIS OF PRESENTATION	ORGANIZATION AND BASIS OF PRESENTATION Organization: Bright Health Group, Inc. and subsidiaries (collectively, “Bright Health,” “we,” “our,” “us,” or the “Company”) was founded in 2015 to transform healthcare. Our mission of Making Healthcare Right. Together. is built upon the belief that by aligning the best local resources in healthcare delivery with the financing of care we can drive a superior consumer experience, optimize clinical outcomes, reduce systemic waste, and lower costs. We are a healthcare company building a national Integrated System of Care in close partnership with our Care Partners. Our differentiated approach is built on alignment, focused on the consumer, and powered by technology. We have two market facing businesses: NeueHealth and Bright HealthCare. NeueHealth provides care delivery and value-based enablement services through our owned and affiliated clinics. Bright HealthCare offers Commercial and Medicare health plan products across the nation. Beginning January 1, 2022, two Direct Contracting Entities (“DCEs”) aligned with our NeueHealth segment began participating in the Centers for Medicare and Medicaid Services' (“CMS”) Global and Professional Direct Contracting model (“DC Model”). Both DCEs assume full risk for the total cost of care of aligned beneficiaries. In April 2022, we announced that Bright HealthCare will be exiting the Commercial marketplace in six states for the 2023 plan year: Illinois, New Mexico, Oklahoma, South Carolina, Utah, and Virginia, as well as discontinuing our employer group business. Basis of Presentation: The condensed consolidated financial statements include the accounts of Bright Health Group, Inc. and all subsidiaries and controlled companies. All intercompany balances and transactions are eliminated upon consolidation. The condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our audited consolidated financial statements, unless the information contained in those disclosures materially changed or is required by GAAP. As such, the condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2021 included in our Form 10-K for the year ended December 31, 2021 (“2021 Form 10-K”). The accompanying condensed consolidated financial statements include all normal recurring adjustments necessary for fair presentation of the interim financial statements. Use of Estimates: The preparation of our condensed consolidated financial statements in conformance with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Our most significant estimates include medical costs payable, risk adjustment revenue and associated payables and receivables, premium deficiency reserve, Direct Contracting performance year receivable and obligation, and valuation and impairment of goodwill and other intangible assets. Actual results could differ from these estimate s. F or the three months ended June 30, 2022, we recognized a change in estimate for risk adjustment of $552.3 million, which included a $93.1 million increase in risk adjustment based on expected final settlement of the 2021 risk adjustment payable, as well as an increase in risk adjustment payable related to 2022 as a result of updated data inputs used to calculate members’ expected full year risk scores. The change in our estimated risk adjustment resulted in an increase in risk adjustment payable in the Condensed Co nsolidated Balance Sheets and a reduction in premium revenue in the Condensed Consolidated Statements of Income (Loss). Going Concern: The condensed consolidated financial statements have been prepared in accordance with GAAP assuming the Company will continue as a going concern. The Company has a history of operating losses, and we generated a net loss of $432.0 million for the six months ended June 30, 2022. These losses, as well as significant growth in consumers in the Bright HealthCare segment, which has required us to set aside additional cash for equity contributions to maintain minimum regulatory amounts, have reduced the cash available to fund operations. Based on our projected cash flows and absent any other action, the Company will require additional liquidity to meet its obligation as they come due in the 12 months following the date the condensed consolidated financial statements are issued. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. In response to these conditions, the Company is in the process of seeking additional financing. The Company has formed a special committee of the Board of Directors and engaged a financial advisor to evaluate financing opportunities. However, the Company may not be able to obtain financing on acceptable terms, as any potential financing will be subject to market conditions that are not within the Company’s control. In the event the Company is unable to obtain additional financing or take other management actions, among other potential consequences, we forecast we will be unable to satisfy our financial covenants under our Credit Agreement. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Performance Guarantees: Through our participation in the DC Model, we determined that our arrangements with the providers of our DCE beneficiaries require us to guarantee their performance to CMS. We recognized our obligation to guarantee their performance for the duration of the performance year on the Condensed Consolidated Balance Sheets. As we fulfill our obligation we ratably amortize the guarantee for the amount that represents the completed portion of the performance obligation as direct contracting revenue on the Condensed Consolidated Statements of Income (Loss). Direct contracting revenue is derived from the estimated annual sum of the capitation payments made to the DCEs for services within the scope of the capitation arrangement with CMS and fee-for-service (“FFS”) payments from CMS made directly to third-party providers for our aligned beneficiaries. For each performance year, the final consideration due to the DCEs by CMS (shared savings) or the consideration due to CMS by the DCEs (shared loss) is reconciled in the year following the performance year. Periodically during the performance year, CMS will measure the shared savings or loss and adjust the performance benchmark and thus the remaining performance obligation if we are in a probable shared loss position. Net loss per share: Prior to 2022, basic net loss per share attributable to common stockholders was computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net losses attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares. Beginning in 2022, we also include our Series A Convertible Perpetual Preferred Stock (“Series A Preferred Stock”) issued in January 2022 as a participating security in the computation of net loss per share pursuant to the two-class method. The two-class method of calculating net income (loss) per share is an allocation method that calculates earnings per share for common stock and participating securities. Under the two-class method, total dividends due to the holders of the Series A Preferred Stock and undistributed earnings allocated to participating securities are subtracted from net income (loss) in determining net income (loss) attributable to common stockholders. Operating Costs: Our operating costs, by functional classification for the three and six months ended June 30, 2022 and 2021, are as follows (in thousand s) : Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Compensation and fringe benefits $ 104,629 $ 77,379 $ 236,695 $ 134,405 Professional fees 75,318 42,303 142,129 81,765 Marketing and selling expenses 79,930 63,988 171,737 114,193 Premium taxes and fees 66,274 44,100 136,055 81,831 Premium deficiency reserve 36,757 — 36,757 — General and administrative expenses 33,858 19,266 74,566 33,706 Other operating expenses 16,554 14,024 34,299 23,400 Total operating costs $ 413,320 $ 261,060 $ 832,238 $ 469,300 Recently Issued and Adopted Accounting Pronouncements: In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”) , which simplifies the accounting for convertible instruments by reducing the number of accounting models available for convertible debt instruments. This guidance eliminates the treasury stock method to calculate diluted earnings per share for convertible instruments and requires the use of the if-converted method. We adopted ASU 2020-06 on January 1, 2022. The adoption did not have a material impact on our financial condition, results of operations or cash flows. There were no other accounting pronouncements that were recently issued and not yet adopted or adopted since our audited consolidated financial statements were issued that had, or are expected to have, a material impact on our consolidated financial position, results of operations, or cash flows.

BUSINESS COMBINATIONS

BUSINESS COMBINATIONS	6 Months Ended
	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
BUSINESS COMBINATIONS	BUSINESS COMBINATIONS Centrum Acquisition: On July 1, 2021, we acquired 75% of the outstanding equity interests of Centrum Medical Holdings, LLC (“Centrum”) for cash consideration of $222.4 million and $75.0 million of common stock, for total purchase consideration of $296.2 million, net of $1.2 million of cash acquired. Centrum is a value-based primary care focused, multi-specialty medical group based in Florida. Centrum primarily operates health centers in Florida and Texas serving Commercial, Medicare, and Medicaid consumers across multiple payors. Centrum is included in our NeueHealth reportable segment. The total purchase consideration for the Centrum acquisition is allocated to tangible and intangible assets acquired and liabilities assumed based on their respective fair values as of the acquisition date. The excess of the purchase price over the net assets acquired is recorded as goodwill, which is predominantly attributable to the incremental financial benefits achievable through Bright Health Group’s integrated care delivery model, whereby Bright HealthCare members are cared for under value-based arrangements with Centrum. This model brings together the financing, distribution, and delivery of high-quality healthcare and provides the opportunity to enhance overall margin potential for the Company. The goodwill from the Centrum acquisition is expected to be deductible for tax purposes. The following table discloses the fair values of assets and liabilities acquired by the Company in the Centrum acquisition (in thousand s) : Accounts receivable $ 1,874 Prepaids and other current assets 627 Property and equipment 2,557 Intangible assets 102,370 Other assets 8,917 Total assets 116,345 Medical payables 19 Accounts payable 359 Other current liabilities 861 Other liabilities 11,636 Total liabilities 12,875 Net identified assets acquired 103,470 Goodwill 275,066 Redeemable noncontrolling interest (82,310) Total purchase consideration, net of cash acquired $ 296,226 Our intangible assets related to the Centrum acquisition consist of trade names with a 15-year useful life, customer relationships with 2 to 15-year useful lives, and a reacquired contract between Bright HealthCare and Centrum with a useful life of 4.5 years. The value of the trade name was determined using the relief of royalty method and the excess earnings method was used to value the customer relationships; both methods are considered Level 3 fair value measurements. The fair value of noncontrolling interest was determined using a market approach and included a discount to account for the lack of marketability of the noncontrolling interest. The acquisition of Centrum would not have had a material impact on our revenue or net loss had it been included in the consolidated results of the Company for the three and six months ended June 30, 2021. Central Health Plan Acquisition: On April 1, 2021, we acquired all of the outstanding shares of Central Health Plan of California, Inc. (“CHP”) for cash consideration of $276.0 million and $79.8 million in Series E preferred stock and $13.9 million of working capital adjustments, for total purchase consideration of $285.6 million, net of $84.1 million of cash acquired. All outstanding shares of Series E preferred stock were converted into shares of common stock automatically immediately prior to the closing of our initial public offering on June 28, 2021. CHP is an insurance provider of MA Health Maintenance Organization (“HMO”) services. CHP is included in our Bright HealthCare reportable segment. The total purchase consideration for the CHP acquisition is allocated to tangible and intangible assets acquired and liabilities assumed based on their respective fair values as of the acquisition date. The excess of the purchase price over the net assets acquired is recorded as goodwill. The goodwill for CHP is attributable to synergies from leveraging CHP’s clinical model and California consumer expertise to continue to expand our MA business in the California market. The goodwill is not deductible for tax purposes. The following table discloses the fair values of assets and liabilities acquired by the Company in the CHP acquisition (in thousand s) : Amount Recognized as of Measurement Amounts Recognized as of Accounts receivable $ 16,361 $ 879 $ 17,240 Short-term investments 19,041 — 19,041 Prepaids and other current assets 25,520 10 25,530 Property and equipment 370 — 370 Intangible assets 102,000 — 102,000 Other assets — 1,249 1,249 Total assets 163,292 2,138 165,430 Medical costs payable 79,450 (3,807) 75,643 Accounts payable 2,371 — 2,371 Other current liabilities 17,212 (9,228) 7,984 Other liabilities 28,622 (2,347) 26,275 Total liabilities 127,655 (15,382) 112,273 Net identified assets acquired 35,637 17,520 53,157 Goodwill 236,037 (3,595) 232,442 Total purchase consideration, net of cash acquired $ 271,674 $ 13,925 $ 285,599 The measurement period adjustments above primarily resulted from obtaining additional information for the valuation of deferred taxes included in other liabilities, to estimate the fair value of the right-of-use lease asset and liability included within other assets and other liabilities, and to recognize post-close working capital true-ups based on additional information. Our intangible assets related to the CHP acquisition consist of customer relationships with a 10-year useful life, trade names with a 15-year useful life and the provider network with a 7-year useful life. The value of the trade name was determined using the relief from royalty method and the excess earnings method was used to value the customer relationships; both methods are considered Level 3 fair value measurements. If CHP had been included in the consolidated results of the Company for the six months ended June 30, 2021, our pro forma revenue would have been $2.1 billion and our pro forma net loss would have been $58.3 million. True Health New Mexico and Zipnosis Acquisitions: On March 31, 2021, we acquired all of the outstanding equity interests of True Health New Mexico, Inc. (“THNM”) for initial cash consideration of $27.5 million and $8.1 million of favorable risk-based capital adjustments, net of cash acquired of $24.1 million, for total purchase consideration of $(4.7) million. THNM is a physician-led health insurance company offering policies available through the commercial market for individual on- and off-exchange and employer-sponsored health coverage. THNM is included in our Bright HealthCare reportable segment. In addition, on March 31, 2021, we acquired Zipnosis, Inc. (“Zipnosis”), which is a telehealth platform that offers virtual care to health systems around the U.S., for aggregate consideration of $73.0 million, including $55.1 million in Series E preferred stock and adjusted for $0.5 million of tangible net equity adjustments. We acquired $3.2 million of cash as part of the Zipnosis acquisition, for net total purchase consideration of $69.8 million. Zipnosis is included in our NeueHealth reportable segment. The total purchase consideration for the THNM and Zipnosis acquisitions is allocated to tangible and intangible assets acquired and liabilities assumed based on their respective fair values as of the acquisition date. The excess of the purchase price over the net assets acquired is recorded as goodwill. The goodwill for THNM is attributable to synergies from leveraging THNM’s strong local clinical model of care and the ability to enter into a new state of strategic interest for future growth and expansion. The goodwill from the Zipnosis acquisition is attributable to benefits from the ability to enhance our proprietary technology platform, DocSquad, and Zipnosis’ attractive virtual care capabilities to enhance Bright Health’s consumer and provider connectivity. The goodwill from the THNM and Zipnosis acquisitions is not deductible for tax purposes. The following table discloses the fair values of assets and liabilities acquired by the Company in the THNM and Zipnosis acquisitions (in thousand s) : THNM Zipnosis Accounts receivable $ 714 $ 1,062 Short-term investments 4,705 — Prepaids and other current assets 8,337 141 Property and equipment — 232 Intangible assets 7,300 9,180 Long-term investments 13,644 — Other non-current assets 1,324 766 Total assets 36,024 11,381 Medical costs payable 12,617 — Accounts payable 14,663 136 Unearned revenue 3,645 120 Other current liabilities 11,406 665 Other liabilities 2,499 2,730 Total liabilities 44,830 3,651 Net identified assets (liabilities) acquired (8,806) 7,730 Goodwill 4,148 62,067 Total purchase consideration, net of cash acquired $ (4,658) $ 69,797 We recognized measurement period adjustments for THNM for post-close working capital true-ups of a $0.7 million reduction in medical costs payable (from the $13.3 million previously reported) and a $8.7 million increase in other current liabilities (from the $2.7 million previously reported) based on additional information. Intangible assets initially recognized related to the THNM acquisition consisted of customer relationships with 10- to 14-year useful lives, trade names with a 15-year useful life and the provider network with a 7-year useful life. In the first quarter of 2022, we fully impaired the intangible assets related to THNM as a result of our decision to no longer offer IFP products in New Mexico for the 2023 plan year and exit the employer business as contracts expire. For the Zipnosis acquisition, our preliminary estimate of intangible assets consists of customer relationships with a 15-year useful life, trade names with a 5-year useful life and developed technology with a 7-year useful life. For these acquisitions the value of the trade names and developed technology was determined using the relief from royalty method and the excess earnings method was used to value the customer relationships; both methods are considered Level 3 fair value measurements. If THNM and Zipnosis had been included in the consolidated results of the Company for the six months ended June 30, 2021, our pro forma revenue would have been $2.0 billion and our pro forma net loss would have been $71.7 million. During the six months ended June 30, 2022, we completed an immaterial business combination which increased goodwill.

INVESTMENTS

INVESTMENTS	6 Months Ended
	Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]
INVESTMENTS	INVESTMENTS Fixed Maturity Securities Available-for-sale securities are reported at fair value as of June 30, 2022 and December 31, 2021. Held-to-maturity securities are reported at amortized cost as of June 30, 2022 and December 31, 2021. The following is a summary of our investment securities as of June 30, 2022 and December 31, 2021 (in thousand s) : June 30, 2022 Amortized Gross Gross Carrying Cash equivalents $ 391,200 $ — $ (15) $ 391,185 Available for sale: U.S. government and agency obligations 901,208 80 (8,788) 892,500 Corporate obligations 518,584 137 (28,928) 489,793 State and municipal obligations 16,757 — (287) 16,470 Certificates of deposit 16,115 — (2) 16,113 Mortgage-backed securities 148,265 617 (9,610) 139,272 Asset-backed securities 74,418 10 (2,974) 71,454 Other 391 — (13) 378 Total available-for-sale securities 1,675,738 844 (50,602) 1,625,980 Held to maturity: U.S. government and agency obligations 4,978 — — 4,978 Certificates of deposit 1,447 — — 1,447 Total held-to-maturity securities 6,425 — — 6,425 Total investments $ 2,073,363 $ 844 $ (50,617) $ 2,023,590 December 31, 2021 Amortized Gross Gross Carrying Cash equivalents $ 192,623 $ — $ — $ 192,623 Available for sale: U.S. government and agency obligations 311,936 259 (2,200) 309,995 Corporate obligations 313,965 326 (1,104) 313,187 State and municipal obligations 16,122 33 (38) 16,117 Certificates of deposit 18,752 — — 18,752 Mortgage-backed securities 38,558 63 (67) 38,554 Other 42,889 13 (30) 42,872 Total available-for-sale securities 742,222 694 (3,439) 739,477 Held to maturity: U.S. government and agency obligations 7,739 — — 7,739 Certificates of deposit 1,447 — — 1,447 Total held-to-maturity securities 9,186 — — 9,186 Total investments $ 944,031 $ 694 $ (3,439) $ 941,286 The fair value of available-for-sale investments, including those that are cash equivalents, with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position at June 30, 2022 and December 31, 2021 were as follows (in thousand s) : June 30, 2022 Less Than 12 Months 12 Months or Greater Total Description of Investments Fair Unrealized Fair Unrealized Fair Unrealized Cash equivalents 48,419 (15) — — 48,419 (15) U.S. government and agency obligations 865,788 (8,143) 15,470 (645) 881,258 (8,788) Corporate obligations 458,430 (28,857) 1,422 (71) 459,852 (28,928) State and municipal obligations 16,469 (287) — — 16,469 (287) Certificates of deposit 2,856 (2) — — 2,856 (2) Mortgage-backed securities 128,791 (9,610) — — 128,791 (9,610) Asset-backed securities 68,580 (2,974) — — 68,580 (2,974) Other 953 (13) — — 953 (13) Total bonds $ 1,590,286 $ (49,901) $ 16,892 $ (716) $ 1,607,178 $ (50,617) December 31, 2021 Less Than 12 Months 12 Months or Greater Total Description of Investments Fair Unrealized Fair Unrealized Fair Unrealized U.S. government and agency obligations 286,823 (2,200) — — 286,823 (2,200) Corporate obligations 234,070 (1,104) — — 234,070 (1,104) State and municipal obligations 10,442 (38) — — 10,442 (38) Mortgage-backed securities 32,715 (67) — — 32,715 (67) Other 29,115 (30) — — 29,115 (30) Total bonds $ 593,165 $ (3,439) $ — $ — $ 593,165 $ (3,439) As of June 30, 2022, we had 2,142 investment positions out of 2,377 that were in an unrealized loss position. As of December 31, 2021, we had 1,343 investment positions out of 1,836 that were in an unrealized loss position. We believe that we will collect the principal and interest due on our debt securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate increases and not by unfavorable changes in the credit quality or issuer credit ratings associated with these securities. In addition, all issuers of debt securities we own remain current on all contractual payments as of June 30, 2022. At each reporting period, we evaluate debt securities for potential impairment when the fair value of the investment is less than its amortized cost, and we intend to sell the securities or it is more likely than not that we will be required to sell the securities before recovery of their amortized cost basis. As of June 30, 2022, we did not have the intent to sell any of the securities in an unrealized loss position, and it is not more likely than not that we will be required to sell these securities before recovery of their amortized cost basis. As of June 30, 2022, the maturity of available-for-sale securities, by contractual maturity, reflected at amortized cost and fair value were as follows (in thousand s) : Amortized Fair Due in one year or less $ 785,073 $ 783,124 Due after one year through five years 540,080 516,463 Due after five years through 10 years 339,726 315,997 Due after 10 years 10,859 10,396 Total debt securities $ 1,675,738 $ 1,625,980 Investment income in the Condensed Consolidated Statements of Income (Loss) for the six months ended June 30, 2022 and 2021, was $6.3 million, and $2.4 million, respectively, and $5.4 million and $1.2 million for the three months ended June 30, 2022 and 2021, respectively, related to our fixed maturity securities. The gross proceeds from the sale of available-for-sale securities for the six months ended June 30, 2022 and 2021 were $157.1 million and $576.1 million, respectively. Realized (losses) gains from our fixed maturity securities of $(2.5) million and $0.2 million are included within total investment income, and reclassified out of accumulated other comprehensive income, for the six months ended June 30, 2022 and 2021, respectively. Equity Securities On April 1, 2021 we completed the purchase of 1.6 million shares of equity securities for aggregate cash consideration of $40.1 million. As of June 30, 2022 and December 31, 2021, the equity securities had a carrying value of $63.2 million and $120.4 million, respectively, which is included in short-term investments in the Condensed Consolidated Balance Sheet. We recognized unrealized (losses) gains of $(16.2) million and $58.5 million in investment income (loss) in the Condensed

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS Basis of fair value measurement: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2: Quoted prices for similar assets or liabilities in active markets or quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability. Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). Certain assets and liabilities are measured at fair value in the condensed consolidated financial statements or have fair values disclosed in the notes to the condensed consolidated financial statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP. For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument see Note 5 to the audited consolidated financial statements included in our 2021 Form 10-K. The following tables set forth our fair value measurements as of June 30, 2022 and December 31, 2021, for assets measured at fair value on a recurring basis (in thousand s): June 30, 2022 Level 1 Level 2 Level 3 Total Assets Cash equivalents $ 303,745 $ 61,483 $ — $ 365,228 Fixed maturity securities, available for sale: U.S. government and agency obligations 865,957 26,543 — 892,500 Corporate obligations — 489,793 — 489,793 State and municipal obligations — 16,470 — 16,470 Certificates of deposit — 16,113 — 16,113 Mortgage-backed securities — 139,272 — 139,272 Asset-backed securities — 71,454 71,454 Other — 378 — 378 Total fixed maturity securities, available for sale: 865,957 760,023 — 1,625,980 Equity securities 63,200 — — 63,200 Total assets at fair value $ 1,232,902 $ 821,506 $ — $ 2,054,408 Liabilities Contingent consideration $ — $ — $ 1,495 $ 1,495 December 31, 2021 Level 1 Level 2 Level 3 Total Assets Cash equivalents $ 192,063 $ 250 $ — $ 192,313 Fixed maturity securities, available for sale: U.S. government and agency obligations 220,801 89,194 — 309,995 Corporate obligations 2,323 310,864 — 313,187 State and municipal obligations — 16,117 — 16,117 Certificates of deposit — 18,752 — 18,752 Mortgage-backed securities 2,404 36,150 — 38,554 Other — 42,872 — 42,872 Total fixed maturity securities, available for sale: 225,528 513,949 — 739,477 Equity securities 120,364 — — 120,364 Total assets at fair value $ 537,955 $ 514,199 $ — $ 1,052,154 Liabilities Contingent consideration $ — $ — $ 1,495 $ 1,495 The following tables set forth the Company’s fair value measurements as of June 30, 2022 and December 31, 2021, for certain financial instruments not measured at fair value on a recurring basis (in thousand s) : June 30, 2022 Level 1 Level 2 Level 3 Total Cash equivalents, held to maturity $ 25,957 $ — $ — $ 25,957 Fixed maturity securities, held to maturity: U.S. government and agency obligations 4,978 — — 4,978 Certificates of deposit — 1,447 — 1,447 Total held to maturity $ 30,935 $ 1,447 $ — $ 32,382 December 31, 2021 Level 1 Level 2 Level 3 Total Cash equivalents, held to maturity $ 310 $ — $ — $ 310 Fixed maturity securities, held to maturity: U.S. government and agency obligations 7,732 — — 7,732 Certificates of deposit — 1,447 — 1,447 Total held to maturity $ 8,042 $ 1,447 $ — $ 9,489 There have been no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy. The contingent consideration liability related to the acquisition of AssociatesMD Medical Group, Inc. is measured using Level 3 inputs based on a formulaic multiple of forecasted 2023 EBITDA per the terms of the purchase agreement discounted back to net present value. The following table presents the changes in fair value of the contingent consideration liability for the six months ended June 30, 2022 and year ended December 31, 2021 (in thousand s) : 2022 2021 Balance at beginning of period $ 1,495 $ 5,716 Change in fair value of contingent consideration — (4,221) Balance at end of period $ 1,495 $ 1,495 The carrying amounts reported on the Condensed Consolidated Balance Sheets for other current financial assets and liabilities approximate fair value due to their short-term nature. These assets and liabilities are not included in the tables above.

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND INTANGIBLE ASSETS	GOODWILL AND INTANGIBLE ASSETS Changes in the carrying value of goodwill by reportable segment were as follows (in thousand s) : Bright HealthCare NeueHealth Gross Carrying Cumulative Gross Carrying Cumulative Balance at December 31, 2021 $ 432,858 $ — $ 402,282 $ — Acquisitions — — 310 — Balance at June 30, 2022 $ 432,858 $ — $ 402,592 $ — The gross carrying value and accumulated amortization for definite-lived intangible assets were as follows (in thousand s) : June 30, 2022 December 31, 2021 Gross Carrying Accumulated Amortization Gross Carrying Accumulated Amortization Customer relationships $ 206,321 $ 31,705 $ 209,421 $ 21,728 Trade names 96,041 9,831 99,241 6,738 Reacquired contract 59,000 13,111 59,000 6,556 Developed technology 6,300 1,125 6,300 675 Other 5,400 1,041 6,400 805 Total $ 373,062 $ 56,813 $ 380,362 $ 36,502 We recognized no impairment expense and $6.7 million of impairment expense on the intangible assets related to our THNM acquisition in operating costs in the Condensed Consolidated Statements of Income (Loss) for the three and six months ended June 30, 2022, respectively. See Note 2 Business Combinations, for additional information on this impairment. There was no impairment expense for the three and six months ended June 30, 2021. Amortization expense relating to intangible assets for the three months ended June 30, 2022 and 2021 was $10.4 million and $6.3 million, respectively, and amortization expense for the six months ended June 30, 2022 and 2021 was $20.9 million and $10.0 million, respectively. Estimated amortization expense relating to intangible assets for the remainder of 2022 and for each of the next five full years ending December 31 is as follows (in thousand s) : 2022 (July-December) $ 20,746 2023 41,471 2024 41,332 2025 41,332 2026 28,104 2027 28,065

MEDICAL COSTS PAYABLE

MEDICAL COSTS PAYABLE	6 Months Ended
	Jun. 30, 2022
Insurance [Abstract]
MEDICAL COSTS PAYABLE	MEDICAL COSTS PAYABLE The following table shows the components of the change in medical costs payable for the six months ended June 30 (in thousand s) : 2022 2021 Medical costs payable - January 1 $ 817,975 $ 249,777 Incurred related to: Current year 3,020,733 1,604,472 Prior year (40,520) 334 Total incurred 2,980,213 1,604,806 Paid related to: Current year 2,111,882 1,183,622 Prior year 636,432 198,059 Total paid 2,748,314 1,381,681 Acquired claims liabilities — 92,718 Medical costs payable - June 30 $ 1,049,874 $ 565,620 Medical costs payable attributable to prior years decreased by $40.5 million and increased by $0.3 million for the six months ended June 30, 2022 and 2021, respectively. Medical costs payable estimates are adjusted as additional information becomes known regarding claims; there were no significant changes to estimation methodologies during the periods. The table below details the components making up the medical costs payable as of June 30 (in thousand s) : June 30, 2022 2021 Claims unpaid $ 102,525 $ 23,040 Provider incentive payable 36,058 64,453 Claims adjustment expense liability 15,655 9,718 Incurred but not reported 895,636 468,409 Total medical costs payable $ 1,049,874 $ 565,620 Medical costs payable are primarily related to the current year. The Company has recorded claims adjustment expense as a component of operating costs in the Condensed Consolidated Statements of Income (Loss).

SHORT-TERM BORROWINGS

SHORT-TERM BORROWINGS	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
SHORT-TERM BORROWINGS	SHORT-TERM BORROWINGS We have a $350.0 million revolving credit agreement with a syndicate of banks (the “Credit Agreement”), which matures on February 28, 2024. During the six months ended June 30, 2022, we repaid the $155.0 million outstanding under the Credit Agreement as of December 31, 2021. As of June 30, 2022, we had no short-term borrowings under the Credit Agreement. The Credit Agreement contains a covenant that requires the Company to maintain a total debt to capitalization ratio of 0.25 to 1.00. The Credit Agreement also contains a covenant that require us to maintain a minimum liquidity of $150.0 million. We were in compliance with our debt covenants as of June 30, 2022.

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
SHARE-BASED COMPENSATION	SHARE-BASED COMPENSATION 2016 Incentive Plan The Company adopted its 2016 Stock Incentive Plan (the “2016 Incentive Plan”) in March 2016. The 2016 Incentive Plan allowed for the Company to grant stock options, restricted stock awards (“RSAs”), and restricted stock units (“RSUs”) to certain employees, consultants and non-employee directors. The 2016 Incentive Plan was initially adopted on March 25, 2016, and most recently amended in December 2020. Following the effectiveness of our 2021 Omnibus Plan (the “2021 Incentive Plan”), no further awards will be granted under the 2016 Incentive Plan. However, all outstanding awards granted under the 2016 Incentive Plan will continue to be governed by the existing terms of the 2016 Incentive Plan and the applicable award agreements. 2021 Incentive Plan The 2021 Incentive Plan (the “2021 Incentive Plan”) was adopted by our Board of Directors on May 21, 2021 and approved by our stockholders on May 25, 2021 and June 5, 2021. The 2021 Incentive Plan allows the Company to grant stock options, RSAs, RSUs, stock appreciation rights, other equity based awards, and cash based incentive awards to certain employees, consultants and non-employee directors. There are 73.4 million shares of common stock authorized for issuance under the 2021 Incentive Plan. As of June 30, 2022, a total of 17.6 million shares of common stock were available for future issuance under the 2021 Incentive Plan. Share-Based Compensation Expense We recognized share-based compensation expense of $53.1 million and $19.1 million for the six months ended June 30, 2022 and 2021, respectively, and $20.2 million and $13.9 million for the three months ended June 30, 2022 and 2021, respectively, which is included in operating costs in the Condensed Consolidated Statements of Income (Loss). Stock Options The Board of Directors, or the Compensation and Human Capital Committee of the Board of Directors, as applicable, determines the exercise price, vesting periods and expiration date at the time of the grant. Stock options granted prior to the third quarter of 2021 generally vest 25% at one year from the grant date, then ratably over the next 36 months with continuous employee service. Stock options granted after the beginning of the third quarter of 2021 generally vest ratably over three years. Option grants generally expire 10 years from the date of grant. The calculated value of each option award is estimated on the date of grant using a Black-Scholes option valuation model that used the following weighted-average assumptions for options granted during the six months ended June 30, 2022: 2022 Risk-free interest rate 1.8 % Expected volatility 54.9 % Expected dividend rate 0.0 % Forfeiture rate 10.1 % Expected life in years 6.0 Risk-free interest rates are based on U.S. Treasury yields in effect at the time of grant. Expected volatilities are based on the historical volatility of our publicly traded industry peers and the implied volatility from exchange-traded options on the Company’s common stock. We use historical data to estimate option forfeitures within the valuation model. The expected lives of options granted represent the period of time that the awards granted are expected to be outstanding based on historical exercise patterns. The activity for stock options for the six months ended June 30, 2022 is as follows (in thousand s, except exercise price and contractual life) : Shares Weighted-Average Weighted-Average Aggregate Outstanding at January 1, 2022 69,244 $ 1.84 8.2 $ 113,908 Granted 7,197 1.80 Exercised (610) 1.10 Forfeited (7,005) 2.05 Expired (623) 2.16 Outstanding at June 30, 2022 68,203 $ 1.82 7.4 $ 16,523 We recognized share-based compensation expense related to stock options of $27.6 million for the six months ended June 30, 2022, which is included in operating costs in the Condensed Consolidated Statements of Income (Loss). The weighted-average grant date fair value of stock options granted during the six months ended June 30, 2022 was $0.95 per share. At June 30, 2022, there was $105.3 million of unrecognized compensation expense related to stock options that is expected to be recognized over a weighted-average period of 2.6 years. Restricted Stock Units RSUs represent the right to receive shares of our common stock at a specified date in the future and generally vest over a three-year period, except for Board of Director grants which generally vest one year from the date of grant. The fair value of RSUs is determined based on the closing market price of our common stock on the date of grant. The following table summarizes RSU award activity for the six months ended June 30, 2022 (in thousand s, except weighted average grant date fair value ) : Number of RSUs Weighted Average Grant Date Fair Value Unvested RSUs at December 31, 2021 15,651 $ 3.98 Granted 26,304 1.75 Vested (67) 8.98 Forfeited (5,236) 3.00 Unvested RSUs at June 30, 2022 36,652 $ 2.61 We recognized share-based compensation expense related to RSUs of $10.5 million for the six months ended June 30, 2022, which is included in operating costs in the Condensed Consolidated Statements of Income (Loss). As of June 30, 2022, there was $65.3 million of unrecognized compensation expense related to the RSU grants, which is expected to be recognized over a weighted-average period of 2.6 years. Performance-based Restricted Stock Units (“PSUs”) In connection with our IPO, our Board of Directors approved the grant of PSUs to members of our executive leadership team. The grant encompassed a total of 14.7 million PSUs, separated into four equal tranches, each of which are eligible to vest based on the achievement of predetermined stock price goals and a minimum service period of 3 years. The fair value of the PSUs was determined using a Monte-Carlo simulation. The following table summarizes PSU award activity for the six months ended June 30, 2022 (in thousand s, except weighted average grant date fair value) : Number of PSUs Weighted Average Grant Date Fair Value Unvested PSUs at December 31, 2021 14,700 $ 9.30 Granted — — Forfeited (2,100) 9.30 Unvested PSUs at June 30, 2022 12,600 $ 9.30

REDEEMABLE CONVERTIBLE PREFERRE

REDEEMABLE CONVERTIBLE PREFERRED STOCK	6 Months Ended
	Jun. 30, 2022
Temporary Equity Disclosure [Abstract]
REDEEMABLE CONVERTIBLE PREFERRED STOCK	REDEEMABLE CONVERTIBLE PREFERRED STOCK Series A Convertible Preferred Stock On December 6, 2021, we entered into an investment agreement with certain subsidiaries of Cigna Corporation (“Cigna”) and certain affiliates of New Enterprise Associates (“NEA”) (collectively, the “Purchasers”) relating to the issuance of 750,000 shares of Series A Preferred Stock, par value $0.0001 per share, for an aggregate purchase price of $750.0 million, or $1,000 per share (the “Issuance”). The close of the Issuance occurred on January 3, 2022 (the “Closing Date”). The Series A Preferred Stock ranks senior to the shares of the Company’s common stock with respect to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. The Preferred Stock has an initial liquidation preference of $1,000 per share, which shall increase by accumulated quarterly dividends that are not paid in cash (“compounded dividends”). Holders of the Series A Preferred Stock are entitled to a dividend at the rate of 5.0% per annum, accruing daily and payable quarterly in arrears and subject to certain adjustments, as set forth in the Certificate of Designations. Dividends will be payable in cash, by increasing the amount of liquidation preference (compounded dividends) with respect to a share of Series A Preferred Stock, or any combination thereof, at the sole discretion of the Company. The Series A Preferred Stock had accrued compounded dividends of $18.4 million as of June 30, 2022. The Series A Preferred Stock will be convertible at the option of the holders into (I) the number of shares of common stock equal to the quotient of (a) the sum of (x) the liquidation preference (reflecting increases for compounded dividends) plus (y) the accrued dividends with respect to each share of Series A Preferred Stock as of the applicable conversion date divided by (b) the conversion price (initially approximately $4.55 per share) as of the applicable conversion date plus (II) cash in lieu of fractional shares, subject to certain anti‑dilution adjustments. At any time after the third anniversary of the Closing Date, if the closing price per share of Common Stock on the New York Stock Exchange was greater than $7.96 for (x) each of at least twenty (20) trading days in any period of thirty (30) consecutive trading days and (y) the last trading day immediately before the Company provides the holders with notice of its election to convert all of the Series A Preferred Stock into the relevant number of shares of common stock, the Company may elect to convert all of the Series A Preferred Stock into the relevant number of shares of common stock. Under the Certificate of Designations, holders of the Series A Preferred Stock are entitled to vote with the holders of the common stock on an as‑converted basis, solely with respect to (i) a change of control transaction (to the extent such change of control transaction is submitted to a vote of the holders of the common stock) or (ii) the issuance of capital stock by the Company in connection with an acquisition by the Company (to the extent such issuance is submitted to a vote of the holders of the common stock), subject to certain restrictions. Holders of the Series A Preferred Stock are entitled to a separate class vote with respect to, among other things, amendments to the Company’s organizational documents that have an adverse effect on the Series A Preferred Stock, authorizations or issuances by the Company of securities that are senior to the Series A Preferred Stock, increases or decreases in the number of authorized shares of Preferred Stock, and issuances of shares of the Series A Preferred Stock after the Closing Date. At any time following the fifth anniversary of the original issuance date, the Company may redeem all of the Series A Preferred Stock for a per share amount in cash equal to: (i) the sum of (A) the liquidation preference (reflecting increases for compounded dividends) thereof plus (B) all accrued dividends as of the applicable redemption date, multiplied by (ii) (A) 105% if the redemption occurs at any time prior to the seventh anniversary of the Closing Date and (B) 100% if the redemption occurs at any time on or after the seventh anniversary of the Closing Date. Upon certain change of control events involving the Company, the holders of the Series A Preferred Stock may, at such holder’s election, convert their shares of Series A Preferred Stock into common stock at the then‑current conversion price or require the Company to purchase all or a portion of such holder’s shares of Preferred Stock that have not been so converted at a purchase price per share of Preferred Stock, payable in cash, equal to the greater of (I) (A) if the change of control effective date occurs at any time prior to the seventh anniversary of the Closing Date, the product of 105% multiplied by the sum of (x) the liquidation preference of such share of Series A Preferred Stock (reflecting increases for compounded dividends) plus (y) the accrued dividends in respect of such share of Series A Preferred Stock as of the change of control purchase date and (B) if the change of control effective date occurs on or after the seventh anniversary of the Closing Date, the sum of (x) the liquidation preference (reflecting increases for compounded dividends) of such share of Series A Preferred Stock plus (y) the accrued dividends in respect of such share of Series A Preferred Stock as of the change of control purchase date and (II) the consideration that would have been payable in connection with such change of control if such share of Series A Preferred Stock had been converted into Common Stock immediately prior to the change of control. We have applied the guidance in ASC 480‑10‑S99‑3A, SEC Staff Announcement: Classification and Measurement of Redeemable Securities

NET LOSS PER SHARE

NET LOSS PER SHARE	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
NET LOSS PER SHARE	NET LOSS PER SHARE The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the three and six months ended June 30, (in thousand s, except for per share amounts) : Three Months Ended Six Months Ended 2022 2021 2022 2021 Net loss attributable to Bright Health Group, Inc. common shareholders $ (284,127) $ (44,518) $ (488,299) $ (69,680) Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic and diluted 629,201 160,942 628,984 150,616 Net loss per share attributable to common stockholders, basic and diluted $ (0.45) $ (0.28) $ (0.78) $ (0.46) The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share because including them would have had an anti-dilutive effect for the six months ended June 30 (in thousand s) : Three Months Ended 2022 2021 Redeemable convertible preferred stock (as converted to common stock) 168,932 — Stock options to purchase common stock 68,203 72,219 Restricted stock units 36,652 — Total 273,787 72,219

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Legal proceedings: In the normal course of business, we could be involved in various legal proceedings such as, but not limited to, the following: lawsuits alleging negligence in care or general liability, violation of regulatory bodies’ rules and regulations, or violation of federal and/or state laws. On January 6, 2022, a putative securities class action lawsuit was filed against us and certain of our officers and directors in the Eastern District of New York. The case is captioned Marquez v. Bright Health Group, Inc. et al., 1:22-cv-00101 (E.D.N.Y.). The lawsuit alleges, among other things, that we made materially false and misleading statements regarding our business, operations, which in turn adversely affected our stock price. An amended complaint was filed on June 24, 2022, which expands on the allegations in the original complaint and alleges a putative class period of June 24, 2021 through March 1, 2022. The amended complaint also adds as defendants the underwriters of our initial public offering. The court has not yet set a motion to dismiss briefing schedule. By letter dated January 28, 2022, we received a demand from a purported shareholder to inspect our books and records pursuant to Delaware law. The demand sought information related to the December 6, 2021 Investment Agreement that the Company entered into with NEA and Cigna. The Company and the shareholder’s counsel executed a confidentiality agreement, and we produced certain books and records in response to the demand. On June 3, 2022, the purported shareholder filed a putative class action complaint against us and our Board of Directors alleging that the standstill provisions and certain transfer restrictions in the Investment Agreement breached fiduciary duties to shareholders. The case is captioned Berger v. Adkins et al., 2022-0487 (Del. Ch.). The complaint seeks declaratory and injunctive relief, and an award of attorneys’ fees, but does not allege damages. Plaintiff also filed a request for expedited discovery and a “prompt trial date.” Plaintiff claims that expedited treatment is necessary because the standstill provisions and transfer restrictions are allegedly interfering with the stockholder franchise. Plaintiff also claims that a trial must be held before December 2022, which is when plaintiff claims that Cigna’s standstill period will expire. The Company filed a motion to dismiss the complaint and an opposition to Plaintiff’s request for expedited treatment. The court has not yet set a schedule for either briefing of the motion to dismiss or trial. We intend to vigorously defend the Company in the above actions, but there can be no assurance that we will be successful in any defense. Based on our assessment of the facts underlying the claims and the degree to which we intend to defend the Company in these matters, the amount or range of reasonably possible losses, if any, cannot be estimated. As a result, we have not accrued for any potential loss as of June 30, 2022 for these actions. Other commitments: As of June 30, 2022, we have $46.1 million outstanding, undrawn letters of credit under the Credit Agreement.

SEGMENT AND GEOGRAPHICAL INFORM

SEGMENT AND GEOGRAPHICAL INFORMATION	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
SEGMENT AND GEOGRAPHICAL INFORMATION	SEGMENTS AND GEOGRAPHIC INFORMATION Our two reportable segments are Bright HealthCare and NeueHealth. The following tables present the reportable segment financial information for the three and six months ended June 30, 2022 and 2021 (in thousand s) : Three Months Ended June 30, 2022 Bright NeueHealth Eliminations Consolidated Premium revenue $ 1,364,834 $ 72,495 $ — $ 1,437,329 Direct contracting revenue — 137,205 — 137,205 Service revenue 34 12,811 — 12,845 Investment income 5,433 (16,184) — (10,751) Total unaffiliated revenue 1,370,301 206,327 — 1,576,628 Affiliated revenue — 215,805 (215,805) — Total segment revenue 1,370,301 422,132 (215,805) 1,576,628 Operating income (loss) (229,602) (18,485) — (248,087) Depreciation and amortization $ 6,034 $ 7,195 $ — $ 13,229 Three Months Ended June 30, 2021 Bright NeueHealth Eliminations Consolidated Premium revenue $ 1,023,759 $ 18,327 $ — $ 1,042,086 Direct contracting revenue — — — — Service revenue 90 11,995 — 12,085 Investment income 1,158 58,511 — 59,669 Total unaffiliated revenue 1,025,007 88,833 — 1,113,840 Affiliated revenue — 25,481 (25,481) — Total segment revenue 1,025,007 114,314 (25,481) 1,113,840 Operating income (loss) (115,964) 56,919 — (59,045) Depreciation and amortization $ 4,583 $ 2,612 $ — $ 7,195 Six Months Ended June 30, 2022 Bright NeueHealth Eliminations Consolidated Premium revenue $ 2,958,335 $ 159,444 $ — $ 3,117,779 Direct contracting revenue — 320,002 — 320,002 Service revenue 70 25,203 — 25,273 Investment income 6,301 (57,152) — (50,851) Total unaffiliated revenue 2,964,706 447,497 — 3,412,203 Affiliated revenue — 595,587 (595,587) — Total segment revenue 2,964,706 1,043,084 (595,587) 3,412,203 Operating income (loss) (336,624) (88,443) — (425,067) Depreciation and amortization $ 12,073 $ 14,197 $ — $ 26,270 Six Months Ended June 30, 2021 Bright NeueHealth Eliminations Consolidated Premium revenue $ 1,865,684 $ 37,033 $ — $ 1,902,717 Direct contracting revenue — — — — Service revenue 90 20,433 — 20,523 Investment income 2,404 62,754 — 65,158 Total unaffiliated revenue 1,868,178 120,220 — 1,988,398 Affiliated revenue — 42,633 (42,633) — Total segment revenue 1,868,178 162,853 (42,633) 1,988,398 Operating income (loss) (140,179) 58,301 — (81,878) Depreciation and amortization $ 6,940 $ 4,836 $ — $ 11,776 As a percentage of our total consolidated revenue, premium revenues and direct contracting revenues from CMS were 35% and 31% for the three months ended June 30, 2022 and 2021, respectively. For the six months ended June 30, 2022 and 2021 premium revenues and direct contracting revenues from CMS were 34% and 28%, respectively. The revenues from CMS are included in premium revenue of our Bright HealthCare segment and direct contracting revenue of our NeueHealth segment. For all periods presented, all of our long-lived assets were located in the United States, and all revenues were earned in the United States. We do not include asset information by reportable segment in the reporting provided to the chief operating decision maker.

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES Income tax was an expense of $2.9 million and benefit of $19.5 million for the three months ended June 30, 2022 and 2021, respectively. For the six months ended June 30, 2022 and 2021, income tax was an expense of $6.1 million and benefit of $18.3 million, respectively. The impact from income taxes varies from the federal statutory rate of 21.0% due to state income taxes, changes in the valuation allowance for deferred tax assets and adjustments for permanent differences. For the three months ended June 30, 2022, the expense largely relates to amortization of originating goodwill from asset acquisitions and estimated state income taxes attributable to income earned in separate filing states without state net operating loss carryforwards. For the three and six months ended June 30, 2021, the benefit largely relates to adjustments to the valuation allowance for federal and state deferred tax assets, as well as the effect of deferred taxes recorded as part of business combination accounting for the Universal Care, Inc. (d.b.a. Brand New Day), THNM, Zipnosis, and Central Health Plan of California acquisitions. We assess whether sufficient future taxable income will be generated to permit the use of deferred tax assets. This assessment includes consideration of the cumulative losses incurred over the three-year period ended June 30, 2022. Such objective evidence limits the ability to consider other subjective evidence, such as the Company’s projections for future earnings. On the basis of this evaluation, we have recorded a valuation allowance for deferred tax assets to the extent that they cannot be

REDEEMABLE NONCONTROLLING INTER

REDEEMABLE NONCONTROLLING INTEREST	6 Months Ended
	Jun. 30, 2022
Noncontrolling Interest [Abstract]
REDEEMABLE NONCONTROLLING INTEREST	REDEEMABLE NONCONTROLLING INTEREST Redeemable noncontrolling interests in our subsidiaries whose redemption is outside of our control are classified as temporary equity. The following table provides details of our redeemable noncontrolling interest activity for the three and six months e nded June 30, 2022 and 2021 (in thousand s) : 2022 2021 Balance at January 1 $ 128,407 $ 39,600 (Losses) earnings attributable to noncontrolling interest (2,681) 288 Measurement adjustment 17,285 329 Balance at March 31 $ 143,011 $ 40,217 Earnings attributable to noncontrolling interest 3,625 640 Tax distributions to noncontrolling interest holders (1,894) — Measurement adjustment 19,712 155 Balance at June 30 $ 164,454 $ 41,012

DIRECT CONTRACTING

DIRECT CONTRACTING	6 Months Ended
	Jun. 30, 2022
Direct Contracting [Abstract]
DIRECT CONTRACTING	DIRECT CONTRACTING Beginning January 1, 2022, we began participating in CMS’ DC Model with two DCEs participating through the global risk arrangement and assuming full risk for the total cost of care of aligned beneficiaries. As part of our participation in the DC Model, we are guaranteeing the performance of our care network of participating and preferred providers. The intention of the DC Model is to enhance the quality of care for Medicare FFS beneficiaries while reducing the administrative burden, supporting a focus on complex, chronically ill patients, and encouraging physician organizations that have not typically participated in Medicare FFS programs to serve Medicare FFS beneficiaries. Key components of the financial agreement for the DC Model include: • Performance Year Benchmark: The target amount for Medicare expenditures on covered services (Medicare Part A and B) furnished to a DCE’s aligned beneficiaries during a performance year. The Performance Year Benchmark will be compared to the DCE’s performance year expenditures. This comparison will be used to calculate shared savings and shared losses. The Performance Year Benchmark is established at the beginning of the performance year utilizing prospective trend estimates and is subject to retrospective trend adjustments, if warranted, before the Financial Reconciliation. • Risk-Sharing Arrangements: Used in determining the percent of savings and losses that DCEs are eligible to receive as shared savings or may be required to repay as shared losses. • Financial Reconciliation: The process by which CMS determines shared savings or shared losses by comparing the calculated total benchmark expenditure for a given DCE’s aligned population to the actual expenditures of that DCE’s aligned beneficiaries over the course of a performance year that includes various risk-mitigation options such as stop-loss reinsurance and risk corridors. • Risk-Mitigation Options: Both DCEs elected to participate in a “stop-loss arrangement” for the current performance year offered by CMS. The “stop-loss arrangement” is designed to reduce the financial uncertainty associated with high-cost expenditures of individual beneficiaries. Additionally, CMS has created a mandatory risk corridor program that allocates the DCE’s shared savings and losses in bands of percentage thresholds, after a deviation of greater than 25.0% of the Performance Year Benchmark. Performance Guarantees Through our participation in the DC Model, we determined that our arrangements with the providers of our DCE beneficiaries require us to guarantee their performance to CMS. At the beginning of the performance year, we recognized the Direct Contracting performance year obligation and receivable for the duration of the performance year. This receivable and obligation were measured at an amount equivalent to the Performance Year Benchmark per CMS that is representative of the expected Medicare expenditures for beneficiaries aligned to our DCEs. As we fulfill our obligation, we amortize the guarantee on a straight-line basis for the amount that represents the completed portion of the performance obligation. The receivable is amortized as we receive payment from CMS or receive CMS reporting detailing out-of-network claims paid by CMS on behalf of our aligned beneficiaries. At the end of each reporting period, we estimate out-of-network claims incurred by beneficiaries aligned to our DCEs but not yet reported and record a reserve for the estimated amount which is included in medical costs payable on the Condensed Consolidated Balance Sheets. For each performance year, the final consideration due to the DCEs by CMS (shared savings) or the consideration due to CMS by the DCEs (shared loss) is reconciled in the year following the performance year. Periodically during the performance year, CMS will measure the shared savings or loss and adjust the performance benchmark and thus the remaining performance obligation if we are in a probable shared loss position. The performance year benchmark is our best estimate of our obligation as we are unable to estimate the potential shared savings or loss due to the “stop-loss arrangement”, risk corridor components of the agreement, and a number of variables including but not limited to risk ratings and benchmark trends that could have an inestimable impact on estimated future payments. There were no financial statement impacts of the performance guarantee at June 30, 2021 or for the three and six-month period then ended. The tables below include the financial statement impacts of the performance guarantee at June 30, 2022 and for the three and six-month period then ended ( in thousands ): June 30, 2022 Direct contracting performance year receivable (1)(2) $ 396,104 Direct contracting performance year obligation (2)(3) 310,603 (1) We estimate there to be $95.3 million in out-of-network claims incurred by beneficiaries aligned to our DCE but not reported as of June 30, 2022; this is included in medical costs payable on the Condensed Consolidated Balance Sheets. (2) In May 2022, we received an updated benchmark from CMS resulting in the reduction of both our Direct contracting performance year receivable and obligation by $97.6 million. (3) This obligation represents the consideration due to providers, net of the shared savings or loss for the period and amortization of the liability. Three Months Ended Six Months Ended Amortization of Direct contracting performance year receivable $ 156,808 $ 231,935 Amortization of Direct contracting performance year obligation 164,404 347,201 Direct contracting revenue 137,205 320,002

ORGANIZATION AND BASIS OF PRE_2

ORGANIZATION AND BASIS OF PRESENTATION (Policies)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation: The condensed consolidated financial statements include the accounts of Bright Health Group, Inc. and all subsidiaries and controlled companies. All intercompany balances and transactions are eliminated upon consolidation. The condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our audited consolidated financial statements, unless the information contained in those disclosures materially changed or is required by GAAP. As such, the condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2021 included in our Form 10-K for the year ended December 31, 2021 (“2021 Form 10-K”). The accompanying condensed consolidated financial statements include all normal recurring adjustments necessary for fair presentation of the interim financial statements.
Use of Estimates	Use of Estimates: The preparation of our condensed consolidated financial statements in conformance with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Our most significant estimates include medical costs payable, risk adjustment revenue and associated payables and receivables, premium deficiency reserve, Direct Contracting performance year receivable and obligation, and valuation and impairment of goodwill and other intangible assets. Actual results could differ from these estimate
Performance Guarantees	Performance Guarantees: Through our participation in the DC Model, we determined that our arrangements with the providers of our DCE beneficiaries require us to guarantee their performance to CMS. We recognized our obligation to guarantee their performance for the duration of the performance year on the Condensed Consolidated Balance Sheets. As we fulfill our obligation we ratably amortize the guarantee for the amount that represents the completed portion of the performance obligation as direct contracting revenue on the Condensed Consolidated Statements of Income (Loss). Direct contracting revenue is derived from the estimated annual sum of the capitation payments made to the DCEs for services within the scope of the capitation arrangement with CMS and fee-for-service (“FFS”) payments from CMS made directly to third-party providers for our aligned beneficiaries. For each performance year, the final consideration due to the DCEs by CMS (shared savings) or the consideration due to CMS by the DCEs (shared loss) is reconciled in the year following the performance year. Periodically during the performance year, CMS will measure the shared savings or loss and adjust the performance benchmark and thus the remaining performance obligation if we are in a probable shared loss position.
Net loss per share	Net loss per share: Prior to 2022, basic net loss per share attributable to common stockholders was computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net losses attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares. Beginning in 2022, we also include our Series A Convertible Perpetual Preferred Stock (“Series A Preferred Stock”) issued in January 2022 as a participating security in the computation of net loss per share pursuant to the two-class method. The two-class method of calculating net income (loss) per share is an allocation method that calculates earnings per share for common stock and participating securities. Under the two-class method, total dividends due to the holders of the Series A Preferred Stock and undistributed earnings allocated to participating securities are subtracted from net income (loss) in determining net income (loss) attributable to common stockholders.
Recently Issued and Adopted Accounting Pronouncements	Recently Issued and Adopted Accounting Pronouncements: In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”) , which simplifies the accounting for convertible instruments by reducing the number of accounting models available for convertible debt instruments. This guidance eliminates the treasury stock method to calculate diluted earnings per share for convertible instruments and requires the use of the if-converted method. We adopted ASU 2020-06 on January 1, 2022. The adoption did not have a material impact on our financial condition, results of operations or cash flows. There were no other accounting pronouncements that were recently issued and not yet adopted or adopted since our audited consolidated financial statements were issued that had, or are expected to have, a material impact on our consolidated financial position, results of operations, or cash flows.

ORGANIZATION AND BASIS OF PRE_3

ORGANIZATION AND BASIS OF PRESENTATION (Tables)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Operating Costs by Functional Classification	Operating Costs: Our operating costs, by functional classification for the three and six months ended June 30, 2022 and 2021, are as follows (in thousand s) : Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Compensation and fringe benefits $ 104,629 $ 77,379 $ 236,695 $ 134,405 Professional fees 75,318 42,303 142,129 81,765 Marketing and selling expenses 79,930 63,988 171,737 114,193 Premium taxes and fees 66,274 44,100 136,055 81,831 Premium deficiency reserve 36,757 — 36,757 — General and administrative expenses 33,858 19,266 74,566 33,706 Other operating expenses 16,554 14,024 34,299 23,400 Total operating costs $ 413,320 $ 261,060 $ 832,238 $ 469,300

BUSINESS COMBINATIONS (Tables)

BUSINESS COMBINATIONS (Tables)	6 Months Ended
	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of Business Acquisitions, by Acquisition	The following table discloses the fair values of assets and liabilities acquired by the Company in the Centrum acquisition (in thousand s) : Accounts receivable $ 1,874 Prepaids and other current assets 627 Property and equipment 2,557 Intangible assets 102,370 Other assets 8,917 Total assets 116,345 Medical payables 19 Accounts payable 359 Other current liabilities 861 Other liabilities 11,636 Total liabilities 12,875 Net identified assets acquired 103,470 Goodwill 275,066 Redeemable noncontrolling interest (82,310) Total purchase consideration, net of cash acquired $ 296,226 The following table discloses the fair values of assets and liabilities acquired by the Company in the CHP acquisition (in thousand s) : Amount Recognized as of Measurement Amounts Recognized as of Accounts receivable $ 16,361 $ 879 $ 17,240 Short-term investments 19,041 — 19,041 Prepaids and other current assets 25,520 10 25,530 Property and equipment 370 — 370 Intangible assets 102,000 — 102,000 Other assets — 1,249 1,249 Total assets 163,292 2,138 165,430 Medical costs payable 79,450 (3,807) 75,643 Accounts payable 2,371 — 2,371 Other current liabilities 17,212 (9,228) 7,984 Other liabilities 28,622 (2,347) 26,275 Total liabilities 127,655 (15,382) 112,273 Net identified assets acquired 35,637 17,520 53,157 Goodwill 236,037 (3,595) 232,442 Total purchase consideration, net of cash acquired $ 271,674 $ 13,925 $ 285,599 The following table discloses the fair values of assets and liabilities acquired by the Company in the THNM and Zipnosis acquisitions (in thousand s) : THNM Zipnosis Accounts receivable $ 714 $ 1,062 Short-term investments 4,705 — Prepaids and other current assets 8,337 141 Property and equipment — 232 Intangible assets 7,300 9,180 Long-term investments 13,644 — Other non-current assets 1,324 766 Total assets 36,024 11,381 Medical costs payable 12,617 — Accounts payable 14,663 136 Unearned revenue 3,645 120 Other current liabilities 11,406 665 Other liabilities 2,499 2,730 Total liabilities 44,830 3,651 Net identified assets (liabilities) acquired (8,806) 7,730 Goodwill 4,148 62,067 Total purchase consideration, net of cash acquired $ (4,658) $ 69,797

INVESTMENTS (Tables)

INVESTMENTS (Tables)	6 Months Ended
	Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Schedule of Debt Securities, Available-for-sale	The following is a summary of our investment securities as of June 30, 2022 and December 31, 2021 (in thousand s) : June 30, 2022 Amortized Gross Gross Carrying Cash equivalents $ 391,200 $ — $ (15) $ 391,185 Available for sale: U.S. government and agency obligations 901,208 80 (8,788) 892,500 Corporate obligations 518,584 137 (28,928) 489,793 State and municipal obligations 16,757 — (287) 16,470 Certificates of deposit 16,115 — (2) 16,113 Mortgage-backed securities 148,265 617 (9,610) 139,272 Asset-backed securities 74,418 10 (2,974) 71,454 Other 391 — (13) 378 Total available-for-sale securities 1,675,738 844 (50,602) 1,625,980 Held to maturity: U.S. government and agency obligations 4,978 — — 4,978 Certificates of deposit 1,447 — — 1,447 Total held-to-maturity securities 6,425 — — 6,425 Total investments $ 2,073,363 $ 844 $ (50,617) $ 2,023,590 December 31, 2021 Amortized Gross Gross Carrying Cash equivalents $ 192,623 $ — $ — $ 192,623 Available for sale: U.S. government and agency obligations 311,936 259 (2,200) 309,995 Corporate obligations 313,965 326 (1,104) 313,187 State and municipal obligations 16,122 33 (38) 16,117 Certificates of deposit 18,752 — — 18,752 Mortgage-backed securities 38,558 63 (67) 38,554 Other 42,889 13 (30) 42,872 Total available-for-sale securities 742,222 694 (3,439) 739,477 Held to maturity: U.S. government and agency obligations 7,739 — — 7,739 Certificates of deposit 1,447 — — 1,447 Total held-to-maturity securities 9,186 — — 9,186 Total investments $ 944,031 $ 694 $ (3,439) $ 941,286
Schedule of Debt Securities, Held-to-maturity	The following is a summary of our investment securities as of June 30, 2022 and December 31, 2021 (in thousand s) : June 30, 2022 Amortized Gross Gross Carrying Cash equivalents $ 391,200 $ — $ (15) $ 391,185 Available for sale: U.S. government and agency obligations 901,208 80 (8,788) 892,500 Corporate obligations 518,584 137 (28,928) 489,793 State and municipal obligations 16,757 — (287) 16,470 Certificates of deposit 16,115 — (2) 16,113 Mortgage-backed securities 148,265 617 (9,610) 139,272 Asset-backed securities 74,418 10 (2,974) 71,454 Other 391 — (13) 378 Total available-for-sale securities 1,675,738 844 (50,602) 1,625,980 Held to maturity: U.S. government and agency obligations 4,978 — — 4,978 Certificates of deposit 1,447 — — 1,447 Total held-to-maturity securities 6,425 — — 6,425 Total investments $ 2,073,363 $ 844 $ (50,617) $ 2,023,590 December 31, 2021 Amortized Gross Gross Carrying Cash equivalents $ 192,623 $ — $ — $ 192,623 Available for sale: U.S. government and agency obligations 311,936 259 (2,200) 309,995 Corporate obligations 313,965 326 (1,104) 313,187 State and municipal obligations 16,122 33 (38) 16,117 Certificates of deposit 18,752 — — 18,752 Mortgage-backed securities 38,558 63 (67) 38,554 Other 42,889 13 (30) 42,872 Total available-for-sale securities 742,222 694 (3,439) 739,477 Held to maturity: U.S. government and agency obligations 7,739 — — 7,739 Certificates of deposit 1,447 — — 1,447 Total held-to-maturity securities 9,186 — — 9,186 Total investments $ 944,031 $ 694 $ (3,439) $ 941,286
Schedule of Available-for-sale Investment With Gross Unrealized Losses	The fair value of available-for-sale investments, including those that are cash equivalents, with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position at June 30, 2022 and December 31, 2021 were as follows (in thousand s) : June 30, 2022 Less Than 12 Months 12 Months or Greater Total Description of Investments Fair Unrealized Fair Unrealized Fair Unrealized Cash equivalents 48,419 (15) — — 48,419 (15) U.S. government and agency obligations 865,788 (8,143) 15,470 (645) 881,258 (8,788) Corporate obligations 458,430 (28,857) 1,422 (71) 459,852 (28,928) State and municipal obligations 16,469 (287) — — 16,469 (287) Certificates of deposit 2,856 (2) — — 2,856 (2) Mortgage-backed securities 128,791 (9,610) — — 128,791 (9,610) Asset-backed securities 68,580 (2,974) — — 68,580 (2,974) Other 953 (13) — — 953 (13) Total bonds $ 1,590,286 $ (49,901) $ 16,892 $ (716) $ 1,607,178 $ (50,617) December 31, 2021 Less Than 12 Months 12 Months or Greater Total Description of Investments Fair Unrealized Fair Unrealized Fair Unrealized U.S. government and agency obligations 286,823 (2,200) — — 286,823 (2,200) Corporate obligations 234,070 (1,104) — — 234,070 (1,104) State and municipal obligations 10,442 (38) — — 10,442 (38) Mortgage-backed securities 32,715 (67) — — 32,715 (67) Other 29,115 (30) — — 29,115 (30) Total bonds $ 593,165 $ (3,439) $ — $ — $ 593,165 $ (3,439)
Schedule of Available-for-sale Securities by Contractual Maturity	As of June 30, 2022, the maturity of available-for-sale securities, by contractual maturity, reflected at amortized cost and fair value were as follows (in thousand s) : Amortized Fair Due in one year or less $ 785,073 $ 783,124 Due after one year through five years 540,080 516,463 Due after five years through 10 years 339,726 315,997 Due after 10 years 10,859 10,396 Total debt securities $ 1,675,738 $ 1,625,980

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables set forth our fair value measurements as of June 30, 2022 and December 31, 2021, for assets measured at fair value on a recurring basis (in thousand s): June 30, 2022 Level 1 Level 2 Level 3 Total Assets Cash equivalents $ 303,745 $ 61,483 $ — $ 365,228 Fixed maturity securities, available for sale: U.S. government and agency obligations 865,957 26,543 — 892,500 Corporate obligations — 489,793 — 489,793 State and municipal obligations — 16,470 — 16,470 Certificates of deposit — 16,113 — 16,113 Mortgage-backed securities — 139,272 — 139,272 Asset-backed securities — 71,454 71,454 Other — 378 — 378 Total fixed maturity securities, available for sale: 865,957 760,023 — 1,625,980 Equity securities 63,200 — — 63,200 Total assets at fair value $ 1,232,902 $ 821,506 $ — $ 2,054,408 Liabilities Contingent consideration $ — $ — $ 1,495 $ 1,495 December 31, 2021 Level 1 Level 2 Level 3 Total Assets Cash equivalents $ 192,063 $ 250 $ — $ 192,313 Fixed maturity securities, available for sale: U.S. government and agency obligations 220,801 89,194 — 309,995 Corporate obligations 2,323 310,864 — 313,187 State and municipal obligations — 16,117 — 16,117 Certificates of deposit — 18,752 — 18,752 Mortgage-backed securities 2,404 36,150 — 38,554 Other — 42,872 — 42,872 Total fixed maturity securities, available for sale: 225,528 513,949 — 739,477 Equity securities 120,364 — — 120,364 Total assets at fair value $ 537,955 $ 514,199 $ — $ 1,052,154 Liabilities Contingent consideration $ — $ — $ 1,495 $ 1,495
Fair Value Disclosure of Asset and Liability Not Measured at Fair Value	The following tables set forth the Company’s fair value measurements as of June 30, 2022 and December 31, 2021, for certain financial instruments not measured at fair value on a recurring basis (in thousand s) : June 30, 2022 Level 1 Level 2 Level 3 Total Cash equivalents, held to maturity $ 25,957 $ — $ — $ 25,957 Fixed maturity securities, held to maturity: U.S. government and agency obligations 4,978 — — 4,978 Certificates of deposit — 1,447 — 1,447 Total held to maturity $ 30,935 $ 1,447 $ — $ 32,382 December 31, 2021 Level 1 Level 2 Level 3 Total Cash equivalents, held to maturity $ 310 $ — $ — $ 310 Fixed maturity securities, held to maturity: U.S. government and agency obligations 7,732 — — 7,732 Certificates of deposit — 1,447 — 1,447 Total held to maturity $ 8,042 $ 1,447 $ — $ 9,489
Schedule of Changes in Fair Value of Contingent Consideration Liability	The following table presents the changes in fair value of the contingent consideration liability for the six months ended June 30, 2022 and year ended December 31, 2021 (in thousand s) : 2022 2021 Balance at beginning of period $ 1,495 $ 5,716 Change in fair value of contingent consideration — (4,221) Balance at end of period $ 1,495 $ 1,495

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS (Tables)	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Changes in the carrying value of goodwill by reportable segment were as follows (in thousand s) : Bright HealthCare NeueHealth Gross Carrying Cumulative Gross Carrying Cumulative Balance at December 31, 2021 $ 432,858 $ — $ 402,282 $ — Acquisitions — — 310 — Balance at June 30, 2022 $ 432,858 $ — $ 402,592 $ —
Schedule of Finite-Lived Intangible Assets	The gross carrying value and accumulated amortization for definite-lived intangible assets were as follows (in thousand s) : June 30, 2022 December 31, 2021 Gross Carrying Accumulated Amortization Gross Carrying Accumulated Amortization Customer relationships $ 206,321 $ 31,705 $ 209,421 $ 21,728 Trade names 96,041 9,831 99,241 6,738 Reacquired contract 59,000 13,111 59,000 6,556 Developed technology 6,300 1,125 6,300 675 Other 5,400 1,041 6,400 805 Total $ 373,062 $ 56,813 $ 380,362 $ 36,502
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Estimated amortization expense relating to intangible assets for the remainder of 2022 and for each of the next five full years ending December 31 is as follows (in thousand s) : 2022 (July-December) $ 20,746 2023 41,471 2024 41,332 2025 41,332 2026 28,104 2027 28,065

MEDICAL COSTS PAYABLE (Tables)

MEDICAL COSTS PAYABLE (Tables)	6 Months Ended
	Jun. 30, 2022
Insurance [Abstract]
Schedule of Liability for Unpaid Claims and Claims Adjustment Expense	The following table shows the components of the change in medical costs payable for the six months ended June 30 (in thousand s) : 2022 2021 Medical costs payable - January 1 $ 817,975 $ 249,777 Incurred related to: Current year 3,020,733 1,604,472 Prior year (40,520) 334 Total incurred 2,980,213 1,604,806 Paid related to: Current year 2,111,882 1,183,622 Prior year 636,432 198,059 Total paid 2,748,314 1,381,681 Acquired claims liabilities — 92,718 Medical costs payable - June 30 $ 1,049,874 $ 565,620 The table below details the components making up the medical costs payable as of June 30 (in thousand s) : June 30, 2022 2021 Claims unpaid $ 102,525 $ 23,040 Provider incentive payable 36,058 64,453 Claims adjustment expense liability 15,655 9,718 Incurred but not reported 895,636 468,409 Total medical costs payable $ 1,049,874 $ 565,620

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The calculated value of each option award is estimated on the date of grant using a Black-Scholes option valuation model that used the following weighted-average assumptions for options granted during the six months ended June 30, 2022: 2022 Risk-free interest rate 1.8 % Expected volatility 54.9 % Expected dividend rate 0.0 % Forfeiture rate 10.1 % Expected life in years 6.0
Schedule of Share-based Payment Arrangement, Option, Activity	The activity for stock options for the six months ended June 30, 2022 is as follows (in thousand s, except exercise price and contractual life) : Shares Weighted-Average Weighted-Average Aggregate Outstanding at January 1, 2022 69,244 $ 1.84 8.2 $ 113,908 Granted 7,197 1.80 Exercised (610) 1.10 Forfeited (7,005) 2.05 Expired (623) 2.16 Outstanding at June 30, 2022 68,203 $ 1.82 7.4 $ 16,523
Share-based Payment Arrangement, Restricted Stock Unit, Activity	The following table summarizes RSU award activity for the six months ended June 30, 2022 (in thousand s, except weighted average grant date fair value ) : Number of RSUs Weighted Average Grant Date Fair Value Unvested RSUs at December 31, 2021 15,651 $ 3.98 Granted 26,304 1.75 Vested (67) 8.98 Forfeited (5,236) 3.00 Unvested RSUs at June 30, 2022 36,652 $ 2.61
Share-based Payment Arrangement, Performance Shares, Activity	The following table summarizes PSU award activity for the six months ended June 30, 2022 (in thousand s, except weighted average grant date fair value) : Number of PSUs Weighted Average Grant Date Fair Value Unvested PSUs at December 31, 2021 14,700 $ 9.30 Granted — — Forfeited (2,100) 9.30 Unvested PSUs at June 30, 2022 12,600 $ 9.30

NET LOSS PER SHARE (Tables)

NET LOSS PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Schedule of Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the three and six months ended June 30, (in thousand s, except for per share amounts) : Three Months Ended Six Months Ended 2022 2021 2022 2021 Net loss attributable to Bright Health Group, Inc. common shareholders $ (284,127) $ (44,518) $ (488,299) $ (69,680) Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic and diluted 629,201 160,942 628,984 150,616 Net loss per share attributable to common stockholders, basic and diluted $ (0.45) $ (0.28) $ (0.78) $ (0.46)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share because including them would have had an anti-dilutive effect for the six months ended June 30 (in thousand s) : Three Months Ended 2022 2021 Redeemable convertible preferred stock (as converted to common stock) 168,932 — Stock options to purchase common stock 68,203 72,219 Restricted stock units 36,652 — Total 273,787 72,219

SEGMENT AND GEOGRAPHICAL INFO_2

SEGMENT AND GEOGRAPHICAL INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Schedule of Reportable Segment Financial Information	The following tables present the reportable segment financial information for the three and six months ended June 30, 2022 and 2021 (in thousand s) : Three Months Ended June 30, 2022 Bright NeueHealth Eliminations Consolidated Premium revenue $ 1,364,834 $ 72,495 $ — $ 1,437,329 Direct contracting revenue — 137,205 — 137,205 Service revenue 34 12,811 — 12,845 Investment income 5,433 (16,184) — (10,751) Total unaffiliated revenue 1,370,301 206,327 — 1,576,628 Affiliated revenue — 215,805 (215,805) — Total segment revenue 1,370,301 422,132 (215,805) 1,576,628 Operating income (loss) (229,602) (18,485) — (248,087) Depreciation and amortization $ 6,034 $ 7,195 $ — $ 13,229 Three Months Ended June 30, 2021 Bright NeueHealth Eliminations Consolidated Premium revenue $ 1,023,759 $ 18,327 $ — $ 1,042,086 Direct contracting revenue — — — — Service revenue 90 11,995 — 12,085 Investment income 1,158 58,511 — 59,669 Total unaffiliated revenue 1,025,007 88,833 — 1,113,840 Affiliated revenue — 25,481 (25,481) — Total segment revenue 1,025,007 114,314 (25,481) 1,113,840 Operating income (loss) (115,964) 56,919 — (59,045) Depreciation and amortization $ 4,583 $ 2,612 $ — $ 7,195 Six Months Ended June 30, 2022 Bright NeueHealth Eliminations Consolidated Premium revenue $ 2,958,335 $ 159,444 $ — $ 3,117,779 Direct contracting revenue — 320,002 — 320,002 Service revenue 70 25,203 — 25,273 Investment income 6,301 (57,152) — (50,851) Total unaffiliated revenue 2,964,706 447,497 — 3,412,203 Affiliated revenue — 595,587 (595,587) — Total segment revenue 2,964,706 1,043,084 (595,587) 3,412,203 Operating income (loss) (336,624) (88,443) — (425,067) Depreciation and amortization $ 12,073 $ 14,197 $ — $ 26,270 Six Months Ended June 30, 2021 Bright NeueHealth Eliminations Consolidated Premium revenue $ 1,865,684 $ 37,033 $ — $ 1,902,717 Direct contracting revenue — — — — Service revenue 90 20,433 — 20,523 Investment income 2,404 62,754 — 65,158 Total unaffiliated revenue 1,868,178 120,220 — 1,988,398 Affiliated revenue — 42,633 (42,633) — Total segment revenue 1,868,178 162,853 (42,633) 1,988,398 Operating income (loss) (140,179) 58,301 — (81,878) Depreciation and amortization $ 6,940 $ 4,836 $ — $ 11,776

REDEEMABLE NONCONTROLLING INT_2

REDEEMABLE NONCONTROLLING INTEREST (Tables)	6 Months Ended
	Jun. 30, 2022
Noncontrolling Interest [Abstract]
Redeemable Noncontrolling Interest	The following table provides details of our redeemable noncontrolling interest activity for the three and six months e nded June 30, 2022 and 2021 (in thousand s) : 2022 2021 Balance at January 1 $ 128,407 $ 39,600 (Losses) earnings attributable to noncontrolling interest (2,681) 288 Measurement adjustment 17,285 329 Balance at March 31 $ 143,011 $ 40,217 Earnings attributable to noncontrolling interest 3,625 640 Tax distributions to noncontrolling interest holders (1,894) — Measurement adjustment 19,712 155 Balance at June 30 $ 164,454 $ 41,012

DIRECT CONTRACTING (Tables)

DIRECT CONTRACTING (Tables)	6 Months Ended
	Jun. 30, 2022
Direct Contracting [Abstract]
Schedule Of Performance Guarantees	The tables below include the financial statement impacts of the performance guarantee at June 30, 2022 and for the three and six-month period then ended ( in thousands ): June 30, 2022 Direct contracting performance year receivable (1)(2) $ 396,104 Direct contracting performance year obligation (2)(3) 310,603 (1) We estimate there to be $95.3 million in out-of-network claims incurred by beneficiaries aligned to our DCE but not reported as of June 30, 2022; this is included in medical costs payable on the Condensed Consolidated Balance Sheets. (2) In May 2022, we received an updated benchmark from CMS resulting in the reduction of both our Direct contracting performance year receivable and obligation by $97.6 million. (3) This obligation represents the consideration due to providers, net of the shared savings or loss for the period and amortization of the liability. Three Months Ended Six Months Ended Amortization of Direct contracting performance year receivable $ 156,808 $ 231,935 Amortization of Direct contracting performance year obligation 164,404 347,201 Direct contracting revenue 137,205 320,002

ORGANIZATION AND BASIS OF PRE_4

ORGANIZATION AND BASIS OF PRESENTATION - Narrative (Details) $ in Thousands		1 Months Ended	3 Months Ended		6 Months Ended
	Jan. 01, 2022 directContractingEntity	Apr. 30, 2022 state	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)
Business Interruption Loss [Line Items]
Number of direct contracting arrangements | directContractingEntity	2
Number of states, exiting Commercial marketplace | state		6
Risk adjustment payable			$ 552,300		$ 916,713	$ 318,758
Net loss			(251,330)	$ (43,723)	$ (431,959)	$ (68,268)
Risk Adjustment Payable, Final Settlement Adjustment
Business Interruption Loss [Line Items]
Risk adjustment payable			$ 93,100

ORGANIZATION AND BASIS OF PRE_5

ORGANIZATION AND BASIS OF PRESENTATION - Schedule of Operating Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Compensation and fringe benefits	$ 104,629	$ 77,379	$ 236,695	$ 134,405
Professional fees	75,318	42,303	142,129	81,765
Marketing and selling expenses	79,930	63,988	171,737	114,193
Premium taxes and fees	66,274	44,100	136,055	81,831
Premium deficiency reserve	36,757	0	36,757	0
General and administrative expenses	33,858	19,266	74,566	33,706
Other operating expenses	16,554	14,024	34,299	23,400
Operating costs	$ 413,320	$ 261,060	$ 832,238	$ 469,300

BUSINESS COMBINATIONS - Narrati

BUSINESS COMBINATIONS - Narrative (Details) - USD ($) $ in Thousands				6 Months Ended	12 Months Ended
	Jul. 01, 2021	Apr. 01, 2021	Mar. 31, 2021	Jun. 30, 2021	Mar. 31, 2022	Jun. 30, 2022
Centrum
Business Acquisition [Line Items]
Voting interest acquired	75%
Payments to acquire businesses, gross	$ (222,400)
Equity interest issued	75,000
Total consideration	296,200
Cash acquired	$ 1,200
Centrum | Trade Names
Business Acquisition [Line Items]
Weighted average useful life	15 years
Centrum | Customer Relationships | Minimum
Business Acquisition [Line Items]
Weighted average useful life	2 years
Centrum | Customer Relationships | Maximum
Business Acquisition [Line Items]
Weighted average useful life	15 years
Centrum | Reacquired contract
Business Acquisition [Line Items]
Weighted average useful life	4 years 6 months
CHP
Business Acquisition [Line Items]
Payments to acquire businesses, gross		$ (276,000)
Equity interest issued		79,800
Cash acquired		84,100
Working capital adjustment					$ 13,900
Purchase consideration		$ 271,674				$ 285,599
Pro forma revenue				$ 2,100,000
Pro forma net loss				$ (58,300)
Measurement period adjustments, Medical costs payable					3,807
CHP | Trade Names
Business Acquisition [Line Items]
Weighted average useful life		15 years
CHP | Customer Relationships
Business Acquisition [Line Items]
Weighted average useful life		10 years
CHP | Provider Network
Business Acquisition [Line Items]
Weighted average useful life		7 years
THNM
Business Acquisition [Line Items]
Payments to acquire businesses, gross			$ (27,500)
Total consideration			4,700
Cash acquired			24,100
Working capital adjustment			$ (8,100)
Purchase consideration						$ (4,658)
Measurement period adjustments, Medical costs payable					$ 700
THNM | Trade Names
Business Acquisition [Line Items]
Weighted average useful life			15 years
THNM | Customer Relationships | Minimum
Business Acquisition [Line Items]
Weighted average useful life			10 years
THNM | Customer Relationships | Maximum
Business Acquisition [Line Items]
Weighted average useful life			14 years
THNM | Provider Network
Business Acquisition [Line Items]
Weighted average useful life			7 years
Zipnosis
Business Acquisition [Line Items]
Payments to acquire businesses, gross			$ (73,000)
Equity interest issued			55,100
Total consideration			69,800
Cash acquired			3,200
Purchase consideration			69,797
Tangible net equity adjustment			$ 500
Zipnosis | Trade Names
Business Acquisition [Line Items]
Weighted average useful life			5 years
Zipnosis | Customer Relationships
Business Acquisition [Line Items]
Weighted average useful life			15 years
Zipnosis | Developed Technology
Business Acquisition [Line Items]
Weighted average useful life			7 years

BUSINESS COMBINATIONS - Schedul

BUSINESS COMBINATIONS - Schedule of Business Acquisitions (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Jun. 30, 2022	Dec. 31, 2021	Jul. 01, 2021	Apr. 01, 2021	Mar. 31, 2021
Business Acquisition, Date of Acquisition [Abstract]
Goodwill		$ 835,450	$ 835,140
Centrum
Business Acquisition, Date of Acquisition [Abstract]
Accounts receivable				$ 1,874
Prepaids and other current assets				627
Property and equipment				2,557
Intangible assets				102,370
Other assets				8,917
Total assets				116,345
Medical payables				19
Accounts payable				359
Other current liabilities				861
Other liabilities				11,636
Total liabilities				12,875
Net identified assets acquired				103,470
Goodwill				275,066
Redeemable noncontrolling interest				(82,310)
Total purchase consideration, net of cash acquired				$ 296,226
CHP
Business Acquisition, Date of Acquisition [Abstract]
Accounts receivable		17,240			$ 16,361
Measurement Period Adjustments, Accounts receivable	$ 879
Short-term investments		19,041			19,041
Measurement Period Adjustments, Short-term investments	0
Prepaids and other current assets		25,530			25,520
Measurement Period Adjustments, Prepaid and other current assets	10
Property and equipment		370			370
Measurement Period Adjustments, Property and equipment	0
Intangible assets		102,000			102,000
Measurement Period Adjustments, Intangible assets	0
Other assets		1,249			0
Measurement Period Adjustments, Other non-current assets	1,249
Total assets		165,430			163,292
Measurement period Adjustments, Total Assets	2,138
Medical payables		75,643			79,450
Measurement Period Adjustments, Medical costs payable	(3,807)
Accounts payable		2,371			2,371
Measurement period Adjustments, Accounts payable	0
Other current liabilities		7,984			17,212
Measurement Period Adjustments, Other current liabilities	(9,228)
Other liabilities		26,275			28,622
Measurement Period Adjustments, Other liabilities	(2,347)
Total liabilities		112,273			127,655
Measurement period Adjustments, Total Liabilities	(15,382)
Net identified assets acquired		53,157			35,637
Measurement period Adjustments, Net Identified Assets Acquired	17,520
Goodwill		232,442			236,037
Measurement Period Adjustments, Goodwill	(3,595)
Total purchase consideration, net of cash acquired		285,599			$ 271,674
Total purchase consideration, net of cash acquired	13,925
THNM
Business Acquisition, Date of Acquisition [Abstract]
Accounts receivable		714
Short-term investments		4,705
Prepaids and other current assets		8,337
Property and equipment		0
Intangible assets		7,300
Long-term investments		13,644
Other assets		1,324
Total assets		36,024
Medical payables		12,617				$ 13,300
Measurement Period Adjustments, Medical costs payable	(700)
Accounts payable		14,663
Unearned revenue		3,645
Other current liabilities		11,406				2,700
Measurement Period Adjustments, Other current liabilities	$ 8,700
Other liabilities		2,499
Total liabilities		44,830
Net identified assets acquired		(8,806)
Goodwill		4,148
Total purchase consideration, net of cash acquired		$ (4,658)
Zipnosis
Business Acquisition, Date of Acquisition [Abstract]
Accounts receivable						1,062
Short-term investments						0
Prepaids and other current assets						141
Property and equipment						232
Intangible assets						9,180
Long-term investments						0
Other assets						766
Total assets						11,381
Medical payables						0
Accounts payable						136
Unearned revenue						120
Other current liabilities						665
Other liabilities						2,730
Total liabilities						3,651
Net identified assets acquired						7,730
Goodwill						62,067
Total purchase consideration, net of cash acquired						$ 69,797

BUSINESS COMBINATIONS - Sched_2

BUSINESS COMBINATIONS - Schedule of Pro Forma Revenue and Net Loss (Details) $ in Millions	6 Months Ended
	Jun. 30, 2021 USD ($)
CHP
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Pro forma revenue	$ 2,100
Pro forma net loss	(58.3)
THNM And Zipnosis
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Pro forma revenue	2,000
Pro forma net loss	$ (71.7)

INVESTMENTS - Schedule of Inves

INVESTMENTS - Schedule of Investment Securities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]
Cash equivalents, Amortized Cost	$ 391,200	$ 192,623
Cash equivalents, Gross Unrealized Gains	0	0
Cash equivalents, Gross Unrealized Losses	(15)	0
Cash equivalents, Carrying Value	391,185	192,623
Amortized Cost	1,675,738	742,222
Gross Unrealized Gains	844	694
Gross Unrealized Losses	(50,602)	(3,439)
Carrying Value	1,625,980	739,477
Debt Securities, Held-to-maturity, Securities [Line Items]
Amortized Cost	6,425	9,186
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Amortized Cost, Total investments	2,073,363	944,031
Gross Unrealized Gains, Total investments	844	694
Gross Unrealized Losses, Total investments	(50,617)	(3,439)
Carrying Value, Total investments	2,023,590	941,286
U.S. government and agency obligations
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	901,208	311,936
Gross Unrealized Gains	80	259
Gross Unrealized Losses	(8,788)	(2,200)
Carrying Value	892,500	309,995
Debt Securities, Held-to-maturity, Securities [Line Items]
Amortized Cost	4,978	7,739
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Corporate obligations
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	518,584	313,965
Gross Unrealized Gains	137	326
Gross Unrealized Losses	(28,928)	(1,104)
Carrying Value	489,793	313,187
State and municipal obligations
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	16,757	16,122
Gross Unrealized Gains	0	33
Gross Unrealized Losses	(287)	(38)
Carrying Value	16,470	16,117
Certificates of deposit
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	16,115	18,752
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(2)	0
Carrying Value	16,113	18,752
Debt Securities, Held-to-maturity, Securities [Line Items]
Amortized Cost	1,447	1,447
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Mortgage-backed securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	148,265	38,558
Gross Unrealized Gains	617	63
Gross Unrealized Losses	(9,610)	(67)
Carrying Value	139,272	38,554
Asset-backed securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	74,418
Gross Unrealized Gains	10
Gross Unrealized Losses	(2,974)
Carrying Value	71,454
Other
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	391	42,889
Gross Unrealized Gains	0	13
Gross Unrealized Losses	(13)	(30)
Carrying Value	$ 378	$ 42,872

INVESTMENTS - Schedule of Inv_2

INVESTMENTS - Schedule of Investments in Continuous Loss Position (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]
Available-for-sale securities, less than 12 months, Fair Value	$ 1,590,286	$ 593,165
Available-for-sale securities, less than 12 months, Unrealized Losses	(49,901)	(3,439)
Available-for-sale securities, 12 months or greater, Fair Value	16,892	0
Available-for-sale securities, 12 months or greater, Unrealized Losses	(716)	0
Available-for-sale securities, Fair Value	1,607,178	593,165
Available-for-sale securities, Unrealized Losses	(50,617)	(3,439)
Cash equivalents
Debt Securities, Available-for-sale [Line Items]
Available-for-sale securities, less than 12 months, Fair Value	48,419
Available-for-sale securities, less than 12 months, Unrealized Losses	(15)
Available-for-sale securities, 12 months or greater, Fair Value	0
Available-for-sale securities, 12 months or greater, Unrealized Losses	0
Available-for-sale securities, Fair Value	48,419
Available-for-sale securities, Unrealized Losses	(15)
U.S. government and agency obligations | Short-Term And Long-Term Investments
Debt Securities, Available-for-sale [Line Items]
Available-for-sale securities, less than 12 months, Fair Value	865,788	286,823
Available-for-sale securities, less than 12 months, Unrealized Losses	(8,143)	(2,200)
Available-for-sale securities, 12 months or greater, Fair Value	15,470	0
Available-for-sale securities, 12 months or greater, Unrealized Losses	(645)	0
Available-for-sale securities, Fair Value	881,258	286,823
Available-for-sale securities, Unrealized Losses	(8,788)	(2,200)
Corporate obligations | Short-Term And Long-Term Investments
Debt Securities, Available-for-sale [Line Items]
Available-for-sale securities, less than 12 months, Fair Value	458,430	234,070
Available-for-sale securities, less than 12 months, Unrealized Losses	(28,857)	(1,104)
Available-for-sale securities, 12 months or greater, Fair Value	1,422	0
Available-for-sale securities, 12 months or greater, Unrealized Losses	(71)	0
Available-for-sale securities, Fair Value	459,852	234,070
Available-for-sale securities, Unrealized Losses	(28,928)	(1,104)
State and municipal obligations | Short-Term And Long-Term Investments
Debt Securities, Available-for-sale [Line Items]
Available-for-sale securities, less than 12 months, Fair Value	16,469	10,442
Available-for-sale securities, less than 12 months, Unrealized Losses	(287)	(38)
Available-for-sale securities, 12 months or greater, Fair Value	0	0
Available-for-sale securities, 12 months or greater, Unrealized Losses	0	0
Available-for-sale securities, Fair Value	16,469	10,442
Available-for-sale securities, Unrealized Losses	(287)	(38)
Certificates of deposit | Short-Term And Long-Term Investments
Debt Securities, Available-for-sale [Line Items]
Available-for-sale securities, less than 12 months, Fair Value	2,856
Available-for-sale securities, less than 12 months, Unrealized Losses	(2)
Available-for-sale securities, 12 months or greater, Fair Value	0
Available-for-sale securities, 12 months or greater, Unrealized Losses	0
Available-for-sale securities, Fair Value	2,856
Available-for-sale securities, Unrealized Losses	(2)
Mortgage-backed securities | Short-Term And Long-Term Investments
Debt Securities, Available-for-sale [Line Items]
Available-for-sale securities, less than 12 months, Fair Value	128,791	32,715
Available-for-sale securities, less than 12 months, Unrealized Losses	(9,610)	(67)
Available-for-sale securities, 12 months or greater, Fair Value	0	0
Available-for-sale securities, 12 months or greater, Unrealized Losses	0	0
Available-for-sale securities, Fair Value	128,791	32,715
Available-for-sale securities, Unrealized Losses	(9,610)	(67)
Asset-backed securities | Short-Term And Long-Term Investments
Debt Securities, Available-for-sale [Line Items]
Available-for-sale securities, less than 12 months, Fair Value	68,580
Available-for-sale securities, less than 12 months, Unrealized Losses	(2,974)
Available-for-sale securities, 12 months or greater, Fair Value	0
Available-for-sale securities, 12 months or greater, Unrealized Losses	0
Available-for-sale securities, Fair Value	68,580
Available-for-sale securities, Unrealized Losses	(2,974)
Other | Short-Term And Long-Term Investments
Debt Securities, Available-for-sale [Line Items]
Available-for-sale securities, less than 12 months, Fair Value	953	29,115
Available-for-sale securities, less than 12 months, Unrealized Losses	(13)	(30)
Available-for-sale securities, 12 months or greater, Fair Value	0	0
Available-for-sale securities, 12 months or greater, Unrealized Losses	0	0
Available-for-sale securities, Fair Value	953	29,115
Available-for-sale securities, Unrealized Losses	$ (13)	$ (30)

INVESTMENTS - Narrative (Detail

INVESTMENTS - Narrative (Details) $ in Thousands, shares in Millions		3 Months Ended		6 Months Ended
	Apr. 01, 2021 USD ($) shares	Jun. 30, 2022 USD ($) investment	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) investment	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($) investment
Debt Securities, Available-for-sale [Line Items]
Number of investment positions in a loss position | investment		2,142		2,142
Number of investments (available-for-sale) | investment		2,377		2,377
Number of securities in unrealized loss position | investment						1,343
Number of investments | investment						1,836
Investment income (loss)		$ (10,751)	$ 59,669	$ (50,851)	$ 65,158
Proceeds from sale of available-for-sale securities		157,100	576,100	157,100	576,100
Realized gains on fixed maturity securities				(2,500)	200
Equity securities purchased (in shares) | shares	1.6
Payments to acquire equity securities	$ 40,100
Equity security market value		63,200		63,200		$ 120,400
Unrealized loss on equity securities		(16,200)		(57,200)
Unrealized gain on equity securities			58,500		62,800
Debt Securities
Debt Securities, Available-for-sale [Line Items]
Investment income (loss)		$ 5,400	$ 1,200	$ 6,300	$ 2,400

INVESTMENTS - Schedule Of Avail

INVESTMENTS - Schedule Of Available-for-sale Securities Maturities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]
Due in one year or less	$ 785,073
Due after one year through five years	540,080
Due after five years through 10 years	339,726
Due after 10 years	10,859
Amortized Cost	1,675,738	$ 742,222
Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]
Due in one year or less	783,124
Due after one year through five years	516,463
Due after five years through 10 years	315,997
Due after 10 years	10,396
Carrying Value	$ 1,625,980	$ 739,477

FAIR VALUE MEASUREMENTS - Sched

FAIR VALUE MEASUREMENTS - Schedule of Fair Value Measurement for Assets on a Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 25,957	$ 310
Carrying Value	1,625,980	739,477
U.S. government and agency obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	892,500	309,995
Corporate obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	489,793	313,187
State and municipal obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	16,470	16,117
Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	16,113	18,752
Mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	139,272	38,554
Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	71,454
Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	378	42,872
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	25,957	310
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	365,228	192,313
Carrying Value	1,625,980	739,477
Equity securities	63,200	120,364
Total assets at fair value	2,054,408	1,052,154
Contingent consideration	1,495	1,495
Fair Value, Recurring | U.S. government and agency obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	892,500	309,995
Fair Value, Recurring | Corporate obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	489,793	313,187
Fair Value, Recurring | State and municipal obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	16,470	16,117
Fair Value, Recurring | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	16,113	18,752
Fair Value, Recurring | Mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	139,272	38,554
Fair Value, Recurring | Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	71,454
Fair Value, Recurring | Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	378	42,872
Fair Value, Recurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	303,745	192,063
Carrying Value	865,957	225,528
Equity securities	63,200	120,364
Total assets at fair value	1,232,902	537,955
Contingent consideration	0	0
Fair Value, Recurring | Level 1 | U.S. government and agency obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	865,957	220,801
Fair Value, Recurring | Level 1 | Corporate obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	0	2,323
Fair Value, Recurring | Level 1 | State and municipal obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	0	0
Fair Value, Recurring | Level 1 | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	0	0
Fair Value, Recurring | Level 1 | Mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	0	2,404
Fair Value, Recurring | Level 1 | Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	0
Fair Value, Recurring | Level 1 | Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	0	0
Fair Value, Recurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	61,483	250
Carrying Value	760,023	513,949
Equity securities	0	0
Total assets at fair value	821,506	514,199
Contingent consideration	0	0
Fair Value, Recurring | Level 2 | U.S. government and agency obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	26,543	89,194
Fair Value, Recurring | Level 2 | Corporate obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	489,793	310,864
Fair Value, Recurring | Level 2 | State and municipal obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	16,470	16,117
Fair Value, Recurring | Level 2 | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	16,113	18,752
Fair Value, Recurring | Level 2 | Mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	139,272	36,150
Fair Value, Recurring | Level 2 | Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	71,454
Fair Value, Recurring | Level 2 | Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	378	42,872
Fair Value, Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Carrying Value	0	0
Equity securities	0	0
Total assets at fair value	0	0
Contingent consideration	1,495	1,495
Fair Value, Recurring | Level 3 | U.S. government and agency obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	0	0
Fair Value, Recurring | Level 3 | Corporate obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	0	0
Fair Value, Recurring | Level 3 | State and municipal obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	0	0
Fair Value, Recurring | Level 3 | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	0	0
Fair Value, Recurring | Level 3 | Mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	0	0
Fair Value, Recurring | Level 3 | Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value
Fair Value, Recurring | Level 3 | Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	$ 0	$ 0

FAIR VALUE MEASUREMENTS - Sch_2

FAIR VALUE MEASUREMENTS - Schedule of Fair Value Measurement of Financial Instruments Not Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 25,957	$ 310
Total held to maturity	32,382	9,489
U.S. government and agency obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held to maturity	4,978	7,732
Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held to maturity	1,447	1,447
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	25,957	310
Total held to maturity	30,935	8,042
Level 1 | U.S. government and agency obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held to maturity	4,978	7,732
Level 1 | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held to maturity	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Total held to maturity	1,447	1,447
Level 2 | U.S. government and agency obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held to maturity	0	0
Level 2 | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held to maturity	1,447	1,447
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Total held to maturity	0	0
Level 3 | U.S. government and agency obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held to maturity	0	0
Level 3 | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Held to maturity	$ 0	$ 0

FAIR VALUE MEASUREMENTS - Sch_3

FAIR VALUE MEASUREMENTS - Schedule of Change in Fair Value of Contingent Consideration (Details) - Contingent Consideration Liability - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 1,495	$ 5,716
Change in fair value of contingent consideration	0	(4,221)
Ending balance	$ 1,495	$ 1,495

GOODWILL AND INTANGIBLE ASSET_2

GOODWILL AND INTANGIBLE ASSETS - Schedule of Goodwill (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Bright HealthCare
Goodwill [Roll Forward]
Gross carrying amount, beginning balance	$ 432,858
Gross carrying amount, acquisitions	0
Gross carrying amount, ending balance	432,858
Cumulative impairment, beginning balance	0
Cumulative impairment, ending balance	0
NeueHealth
Goodwill [Roll Forward]
Gross carrying amount, beginning balance	402,282
Gross carrying amount, acquisitions	310
Gross carrying amount, ending balance	402,592
Cumulative impairment, beginning balance	0
Cumulative impairment, ending balance	$ 0

GOODWILL AND INTANGIBLE ASSET_3

GOODWILL AND INTANGIBLE ASSETS - Schedule of Definite-lived Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 373,062	$ 380,362
Accumulated Amortization	56,813	36,502
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	206,321	209,421
Accumulated Amortization	31,705	21,728
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	96,041	99,241
Accumulated Amortization	9,831	6,738
Reacquired contract
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	59,000	59,000
Accumulated Amortization	13,111	6,556
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	6,300	6,300
Accumulated Amortization	1,125	675
Other
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	5,400	6,400
Accumulated Amortization	$ 1,041	$ 805

GOODWILL AND INTANGIBLE ASSET_4

GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 10,400,000	$ 6,300,000	$ 20,900,000	$ 10,000,000
Impairment of intangible assets	$ 0	$ 0	$ 6,720,000	$ 0

GOODWILL AND INTANGIBLE ASSET_5

GOODWILL AND INTANGIBLE ASSETS - Schedule of Intangible Asset Amortization Expense (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2022 (July-December)	$ 20,746
2023	41,471
2024	41,332
2025	41,332
2026	28,104
2027	$ 28,065

MEDICAL COSTS PAYABLE - Change

MEDICAL COSTS PAYABLE - Change in Medical Costs Payable (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Medical costs payable - January 1	$ 817,975	$ 249,777
Incurred related to:
Current year	3,020,733	1,604,472
Prior year	(40,520)	334
Total incurred	2,980,213	1,604,806
Paid related to:
Current year	2,111,882	1,183,622
Prior year	636,432	198,059
Total paid	2,748,314	1,381,681
Acquired claims liabilities	0	92,718
Medical costs payable - June 30	$ 1,049,874	$ 565,620

MEDICAL COSTS PAYABLE - Narrati

MEDICAL COSTS PAYABLE - Narrative (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Insurance [Abstract]
Medical costs payable, increase (decrease) to prior years	$ (40.5)	$ 0.3

MEDICAL COSTS PAYABLE - Compone

MEDICAL COSTS PAYABLE - Components of Medical Costs Payable (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Insurance [Abstract]
Claims unpaid	$ 102,525		$ 23,040
Provider incentive payable	36,058		64,453
Claims adjustment expense liability	15,655		9,718
Incurred but not reported	895,636		468,409
Total medical costs payable	$ 1,049,874	$ 817,975	$ 565,620	$ 249,777

SHORT-TERM BORROWINGS (Details)

SHORT-TERM BORROWINGS (Details)		1 Months Ended	6 Months Ended
	Mar. 01, 2021 USD ($)	Jul. 31, 2022 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)
Line of Credit Facility [Line Items]
Repayments of lines of credit			$ 155,000,000
Short-term borrowings			0	$ 155,000,000
Subsequent Event
Line of Credit Facility [Line Items]
Effective annual interest rate		8.32%
Series A Preferred Stock | Preferred Stock | Subsequent Event
Line of Credit Facility [Line Items]
Borrowings		$ 153,900,000
Revolving Credit Facility | Line of Credit
Line of Credit Facility [Line Items]
Revolving credit facility	$ 350,000,000
Debt to capitalization ratio	0.25
Minimum liquidity requirement			$ 150,000,000

SHARE-BASED COMPENSATION - Narr

SHARE-BASED COMPENSATION - Narrative (Details) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($) shares	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) vestingTranche $ / shares shares	Jun. 30, 2021 USD ($)	Dec. 31, 2021 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares) | shares	73,400,000		73,400,000
Number of shares available for grant (in shares) | shares	17,600,000		17,600,000
Share-based compensation expense	$ 20.2	$ 13.9	$ 53.1	$ 19.1
Weighted-average grant date fair value of stock options granted (in dollars per share) | $ / shares			$ 0.95
Unrecognized compensation expense	105.3		$ 105.3
Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense			$ 27.6
Vesting period			3 years
Option grants expiration			10 years
Unrecognized compensation expense, weighted average recognition period			2 years 7 months 6 days
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense			$ 10.5
Vesting period			3 years
Unrecognized compensation expense, weighted average recognition period			2 years 7 months 6 days
Unrecognized compensation expense, other than options	$ 65.3		$ 65.3
Outstanding (in shares) | shares	36,652,000		36,652,000		15,651,000
Restricted stock units | Board of Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			1 year
PSU's
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense			$ 15
Unrecognized compensation expense, weighted average recognition period			2 years
Unrecognized compensation expense, other than options	$ 70.3		$ 70.3
Outstanding (in shares) | shares	12,600,000		12,600,000		14,700,000
PSU's | Leadership Team
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding (in shares) | shares	14,700,000		14,700,000
Number of vesting tranches (in vesting tranches) | vestingTranche			4
Service period			3 years
Tranche one | Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting				25%
Vesting period				1 year
Tranche two | Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period				36 months

SHARE-BASED COMPENSATION - Sche

SHARE-BASED COMPENSATION - Schedule of Stock Option Valuation Assumptions (Details)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Risk-free interest rate	1.80%
Expected volatility	54.90%
Expected dividend rate	0%
Forfeiture rate	10.10%
Expected life in years	6 years

SHARE-BASED COMPENSATION - Sc_2

SHARE-BASED COMPENSATION - Schedule of Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Shares
Beginning balance (in shares)	69,244
Granted (in shares)	7,197
Exercised (in shares)	(610)
Forfeited (in shares)	(7,005)
Expired (in shares)	(623)
Ending balance (in shares)	68,203	69,244
Weighted-Average Exercise Price
Beginning balance (in dollars per share)	$ 1.84
Granted (in dollars per share)	1.80
Exercised (in dollars per share)	1.10
Forfeited (in dollars per share)	2.05
Expired (in dollars per share)	2.16
Ending balance (in dollars per share)	$ 1.82	$ 1.84
Weighted-Average Remaining Contractual Life (In Years)	7 years 4 months 24 days	8 years 2 months 12 days
Aggregate Intrinsic Value
Beginning balance	$ 113,908
Ending balance	$ 16,523	$ 113,908

SHARE-BASED COMPENSATION - Sc_3

SHARE-BASED COMPENSATION - Schedule of RSU and PSU Activity (Details) shares in Thousands	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Restricted stock units
Number of Awards
Beginning balance (in shares) | shares	15,651
Granted (in shares) | shares	26,304
Vested (in shares) | shares	(67)
Canceled (in shares) | shares	(5,236)
Ending balance (in shares) | shares	36,652
Weighted Average Grant Date Fair Value
Beginning balance (in dollars per share) | $ / shares	$ 3.98
Granted (in dollars per share) | $ / shares	1.75
Vested (in dollars per share) | $ / shares	8.98
Canceled (in dollars per share) | $ / shares	3
Ending balance (in dollars per share) | $ / shares	$ 2.61
PSU's
Number of Awards
Beginning balance (in shares) | shares	14,700
Granted (in shares) | shares	0
Canceled (in shares) | shares	(2,100)
Ending balance (in shares) | shares	12,600
Weighted Average Grant Date Fair Value
Beginning balance (in dollars per share) | $ / shares	$ 9.30
Granted (in dollars per share) | $ / shares	0
Canceled (in dollars per share) | $ / shares	9.30
Ending balance (in dollars per share) | $ / shares	$ 9.30

REDEEMABLE CONVERTIBLE PREFER_2

REDEEMABLE CONVERTIBLE PREFERRED STOCK (Details) $ / shares in Units, $ in Thousands		3 Months Ended			6 Months Ended
	Dec. 06, 2021 USD ($) tradingDay $ / shares shares	Mar. 31, 2022 USD ($) shares	Jun. 30, 2021 USD ($) shares	Mar. 31, 2021 USD ($) shares	Jun. 30, 2022 USD ($) $ / shares	Dec. 31, 2021 $ / shares
Temporary Equity Disclosure [Abstract]
Issuance of preferred stock (in shares) | shares	750,000	750,000	2,067,000	1,420,000
Convertible preferred stock, par value (in dollars per share)	$ 0.0001				$ 0.0001	$ 0.0001
Issuance of preferred stock | $	$ 750,000	$ 747,481	$ 79,807	$ 55,137
Redemption price (in dollars per share)	$ 1,000
Temporary Equity, Liquidation Preference Per Share	$ 1,000
Dividend rate	5%
Accretion to redemption value | $					$ 18,400
Conversion price (in dollars per share)	$ 4.55
Volume weighted average price of common stock (in dollars per share)	$ 7.96
Number of threshold trading days | tradingDay	20
Number of consecutive trading days | tradingDay	30
Multiplier for accrued and unpaid dividends, before seventh anniversary	105%
Multiplier for accrued and unpaid dividends, after seventh anniversary	100%
Liquidation preference	105%
Fair value of preferred stock | $					$ 2,500

NET LOSS PER SHARE - Schedule o

NET LOSS PER SHARE - Schedule of Net Loss Per share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Earnings Per Share [Abstract]
Net loss attributable to Bright Health Group, Inc. common shareholders, basic	$ (284,127)	$ (44,518)	$ (488,299)	$ (69,680)
Net loss attributable to Bright Health Group, Inc. common shareholders, diluted	$ (284,127)	$ (44,518)	$ (488,299)	$ (69,680)
Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic (in shares)	629,201	160,942	628,984	150,616
Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, diluted (in shares)	629,201	160,942	628,984	150,616
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.45)	$ (0.28)	$ (0.78)	$ (0.46)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.45)	$ (0.28)	$ (0.78)	$ (0.46)

NET LOSS PER SHARE - Schedule_2

NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded From Net Loss Per Share (Details) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	273,787	72,219
Redeemable convertible preferred stock (as converted to common stock)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	168,932	0
Stock options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	68,203	72,219
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	36,652	0

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) $ in Millions	Jun. 30, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Letters of credit outstanding	$ 46.1

SEGMENT AND GEOGRAPHICAL INFO_3

SEGMENT AND GEOGRAPHICAL INFORMATION - Narrative (Details) - segment	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting Information [Line Items]
Number of reportable segments			2
Revenue Benchmark | Customer Concentration Risk | CMS
Segment Reporting Information [Line Items]
Concentration risk	35%	31%	34%	28%

SEGMENT AND GEOGRAPHICAL INFO_4

SEGMENT AND GEOGRAPHICAL INFORMATION - Schedule of Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting Information [Line Items]
Premium revenue	$ 1,437,329	$ 1,042,086	$ 3,117,779	$ 1,902,717
Direct contracting revenue	137,205	0	320,002	0
Service revenue	12,845	12,085	25,273	20,523
Investment income (loss)	(10,751)	59,669	(50,851)	65,158
Total revenue	(1,576,628)	(1,113,840)	(3,412,203)	(1,988,398)
Operating income (loss)	(248,087)	(59,045)	(425,067)	(81,878)
Depreciation and amortization	13,229	7,195	26,270	11,776
Bright HealthCare
Segment Reporting Information [Line Items]
Premium revenue	1,364,834	1,023,759	2,958,335	1,865,684
Direct contracting revenue	0	0	0	0
Service revenue	34	90	70	90
Investment income (loss)	5,433	1,158	6,301	2,404
Total revenue	(1,370,301)	(1,025,007)	(2,964,706)	(1,868,178)
NeueHealth
Segment Reporting Information [Line Items]
Premium revenue	72,495	18,327	159,444	37,033
Direct contracting revenue	137,205	0	320,002	0
Service revenue	12,811	11,995	25,203	20,433
Investment income (loss)	(16,184)	58,511	(57,152)	62,754
Total revenue	(206,327)	(88,833)	(447,497)	(120,220)
Operating Segments | Bright HealthCare
Segment Reporting Information [Line Items]
Total revenue	(1,370,301)	(1,025,007)	(2,964,706)	(1,868,178)
Operating income (loss)	(229,602)	(115,964)	(336,624)	(140,179)
Depreciation and amortization	6,034	4,583	12,073	6,940
Operating Segments | NeueHealth
Segment Reporting Information [Line Items]
Total revenue	(422,132)	(114,314)	(1,043,084)	(162,853)
Operating income (loss)	(18,485)	56,919	(88,443)	58,301
Depreciation and amortization	7,195	2,612	14,197	4,836
Intersegment Eliminations
Segment Reporting Information [Line Items]
Total revenue	215,805	25,481	595,587	42,633
Intersegment Eliminations | NeueHealth
Segment Reporting Information [Line Items]
Total revenue	$ 215,805	$ 25,481	$ 595,587	$ 42,633

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income tax (benefit) expense	$ 2,904	$ (19,464)	$ 6,144	$ (18,298)

REDEEMABLE NONCONTROLLING INT_3

REDEEMABLE NONCONTROLLING INTEREST - Schedule of Redeemable Noncontrolling Interest (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Beginning balance	$ 143,011	$ 128,407	$ 40,217	$ 39,600	$ 128,407	$ 39,600
(Losses) earnings attributable to noncontrolling interest	3,625	(2,681)	640	288
Tax distribution to noncontrolling interest holders					(1,894)	0
Measurement adjustment	19,712	17,285	155	329
Ending balance	$ 164,454	$ 143,011	$ 41,012	$ 40,217	$ 164,454	$ 41,012

DIRECT CONTRACTING - Narrative

DIRECT CONTRACTING - Narrative (Details) - directContractingEntity		6 Months Ended
	Jan. 01, 2022	Jun. 30, 2022
Direct Contracting [Abstract]
Number of direct contracting arrangements	2
Threshold of performance year benchmark		25%

DIRECT CONTRACTING (Details)

DIRECT CONTRACTING (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Direct Contracting [Abstract]
Direct contracting performance year receivable	$ 396,104		$ 396,104		$ 0
Direct contracting performance year obligation	310,603		310,603		$ 0
Out-of-network claims incurred	95,300		95,300
Amortization of Direct contracting performance year receivable	156,808		231,935
Amortization of Direct contracting performance year obligation	164,404		347,201
Direct contracting revenue	137,205	$ 0	320,002	$ 0
Performance year receivables and obligations	$ 97,600		$ 97,600